

---

Drug Discovery and Evaluation  
Pharmacological Assays

**Springer**

*Berlin*

*Heidelberg*

*New York*

*Barcelona*

*Hong Kong*

*London*

*Milan*

*Paris*

*Tokyo*

---

H. Gerhard Vogel (Ed.)

# Drug Discovery and Evaluation

## Pharmacological Assays

Second Completely Revised, Updated, and Enlarged Edition

Including a CD-ROM



Springer

---

## Editor

*Prof. Dr. med. Dr. s.c. H. Gerhard Vogel*  
Johann Wolfgang Goethe Universität  
Frankfurt am Main  
Germany

ISBN 3-540-42396-6 Springer-Verlag Berlin Heidelberg New York

### Library of Congress Cataloging-in-Publication Data

Drug discovery and evaluation : pharmacological assays / H. Gerhard Vogel ...  
(ed.).-- 2nd ed.

p. ; cm.

Includes bibliographical references.

ISBN 3540423966 (alk. paper)

1. Pharmacology, Experimental. 2. Drugs--Design. 3. Drugs--Testing. I. Vogel, H. Gerhard, 1927-

[DNLM: 1. Drug Design--Laboratory Manuals. 2. Drug Evaluation--methods--Laboratory Manuals. 3. Drug Evaluation, Preclinical--methods--Laboratory Manuals. QV 744 D79335 2002] RM301.25 .V64 2002  
615'.7--dc21

2002019340

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer-Verlag. Violations are liable for prosecution under the German Copyright Law.

Springer-Verlag Berlin Heidelberg New York  
a member of the BertelsmannSpringer Science+Business Media GmbH

<http://www.springer.de>

© Springer-Verlag Berlin Heidelberg 2002  
Printed in Germany

The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product liability: The publisher cannot guarantee the accuracy of any information about dosage and application thereof contained in this book. In every individual case the user must check such information by consulting the relevant literature.

Cover Design: *design & production*, Heidelberg  
Dataconversion: Büro Stasch, Bayreuth

SPIN: 10841880 14/3130/ag - 5 4 3 2 1 0 - Printed on acid-free paper

---

## Preface to the second edition

The first edition of “Drug Discovery and Evaluation – Pharmacological Assays” has been well accepted by a broad readership ranging from experienced pharmacologists to students of pharmacology. Therefore, already after a short period of time the question for a second edition arose.

The first edition was mainly centered around the personal laboratory experience of the editors and the contributors. The second edition tries to close evident gaps.

The input of biochemistry to pharmacology has grown. Molecular pharmacology puts more emphasis on the mode of action of drugs, albeit it becomes clear that the activities of most drugs are not confined to one single mode of action. Studies in single cells become more and more popular, however, they do not cover the complexity of a whole organism. Possible side effects of drugs can be better detected in whole animals than in single cells. Therefore, the new requirements of the health authorities on safety pharmacology put emphasis on experiments not only in whole anesthetized animals but in conscious ones. The second edition of this book takes note of these requirements and devotes special chapters for each indication to safety pharmacology.

Molecular biology also introduced new methods to pharmacology, such as the polymerase chain reaction (PCR), reverse PCR, Northern, Western and Southern blotting. Very recently, microarray technology, proteomics, and mass spectroscopy were added as novel *in vitro* methods. Furthermore, genetically modified animals have been created which resemble human diseases. Pharmacogenomics has already begun to influence pharmacology and even will have greater input in the future. Special attention is given to these new achievements in various chapters of the book.

The editor and the co-editors are well aware that the rapid progress in biology during the next decades will change the methodological approach. Electronic media will help the researcher for continuous information. However, it becomes more and more evident, that young pharmacologists have only insufficient training in the classical pharmacological methodology. Searching for these methods, e.g., for safety pharmacology, the researchers cannot find sufficient information on the methodological details in the electronic data bases currently available. This book covering the pharmacological methods of more than hundred years may be of help.

The guidelines concerning the care and use of laboratory animals have been updated.

A change in paradigm of pharmacological research has been claimed but superiorities of these new approaches compared to the old ones have still to be proven. To address this, an introductory chapter on new strategies in drug discovery and evaluation has been added, including combinatorial chemistry; high throughput screening, ultra high throughput screening and high content screening; pharmacogenomics, proteomics and array technology. Some critical thoughts on errors in screening procedures have been added.

At this place, we would like to express our sincere thanks to all colleagues who contributed to the new and to the first edition of this book. Their names and their positions are given alphabetically.

March 2002

H. Gerhard Vogel  
Also in the name of the co-editors



---

## Preface to the first edition

This book is intended to be an aid for experienced pharmacologists as well as for newcomers in the field of experimental pharmacology. The student in pharmacology, the pharmacist and the medicinal chemist will find a survey of pharmacological assays that can be used for a given indication and for which methods have demonstrated their relevance. The researchers working in special fields of pharmacology will find assays in other, unfamiliar areas which might help to expand their own research.

Certain therapeutic domains, such as cardiovascular, respiratory and renal disorders, psychiatry and neurology, peripheral nerve function, pain and rheumatic diseases, metabolic and endocrine diseases including diseases of the gastrointestinal tract, are discussed in this book.

Each chapter is divided into pharmacological classes, e.g., anxiolytics, anti-epileptics, neuroleptics, antidepressants, or anti-Parkinson drugs. For each class, in vitro methods, tests on isolated organs and in vivo methods are described.

For each method the purpose and rationale are given first, followed by a description of the procedure, evaluation of the data, modifications of the method described in the literature, and the relevant references. If possible, a critical assessment of the method based on personal experience is added. The hints for modifications of the method and the extended reference list will be of value for the experienced pharmacologist.

A few words for the justification for a book of this kind:

In 1959, A. J. Lehman, Director of the Division of Pharmacology at the Food and Drug Administration, USA, wrote:

... Pharmacologists are individualists. Like most scientists they are seldom willing to copy each other's techniques in detail, and so their methods vary from one to the other. Nevertheless, there are basic principles and techniques which must be applied to establish the safety of a new drug.

Visitors could also read a sticker in his office:

You too can learn pharmacology, in only three lessons: each of them lasting ten years.

Pharmacologists have always used methods from neighboring disciplines; in the past, e.g. from anatomy, pathology, surgery, zoology and predominantly physiology. Useful methods also came from electrophysiology and the behavioral sciences. Earlier drug discovery was almost exclusively based on animal experiments, clinical observations and serendipity.

In recent years, a major input has come from biochemistry. The effect of many drugs in human therapy could be explained biochemically as effects on specific enzymes or receptors. With the detection of more and more receptor subtypes, the activity spectrum of a single compound became more and more complicated. At present, molecular biology provides pharmacologists with human receptors and ion channels expressed in mammalian cells in culture. This avoids the apparently existing species differences, but the multitude of natural and perhaps artificial subtypes raises the question of physiological and pathological relevance.

The challenge for the pharmacologist always will be to correlate *in vitro* data with *in vivo* findings, bearing in mind the old saying: “*In vitro simplicitas, in vivo veritas*”. The effects found in tissue cultures are quite often not typical for an intact organism.

Pharmacologists, especially in industry, have the task to find new drugs for human therapy by using appropriate models. Pharmacological models have to be relevant, that means they should predict the intended therapeutic indications. A pharmacological model can be considered relevant or correlational, if the effects obtained correlate with results observed in human therapy.

To be relevant or “correlational”, a model has to fulfill some basic criteria:

- First, the model must be sensitive in a dose-dependent fashion to standard compounds that are known to possess the desired therapeutic property.
- Second, the relative potency of known active agents in the model should be comparable to their relative potency in clinical use.
- Third, the model should be selective, i.e. the effects of known agents in this therapeutic indication should be distinguishable from effects of drugs for other indications. Positive data with a new compound allow the prediction of a therapeutic effect in patients.

If new assays are applied to indications for which no effective drug is known, there must be sufficient evidence that this model is relevant for the pathological status in this indication.

The methods presented in this book have been selected according to these criteria.

Considerable discussion is going on about the necessity of animal experiments. One has to accept that only the whole animal can reflect the complexity of a human being. Even an experiment with human volunteers is only a model, albeit a highly relevant one, to investigate therapeutic effects in patients. The degree of relevance increases from isolated molecules (e.g. receptors or enzymes) to organelles, to organs up to conscious animals and human volunteers.

Without any doubt, animal experiments are necessary for the discovery and evaluation of drugs. However, they should be performed only if they are necessary and well conceived.

In Chapter N, regulations existing in various countries concerning the care and use of laboratory animals are listed. Furthermore, guidelines for anesthesia, blood collection and euthanasia in laboratory animals are given. In carrying out animal experiments, one must adhere strictly to these guidelines. Following these rules and planing the experiments well, will eliminate or minimize pain and discomfort to the animal. The methods described in this book had the welfare of the animals as well as the benefit of the procedure for the well-being of mankind in mind.

Here, we would like to express our sincere thanks to all colleagues who contributed to this book. Their names and positions are given alphabetically below.

Autumn 1996

H. Gerhard Vogel  
Wolfgang H. Vogel



---

## Editor and co-editors

### Editor

*Prof. Dr. Dr. H. Gerhard Vogel*    Johann Wolfgang Goethe-Universität, Frankfurt

### Coeditors

*Prof. Dr. Wolfgang H. Vogel*    Jefferson Medical College, Thomas Jefferson University, Department of Pharmacology, Philadelphia, USA

*Prof. Dr. Bernward A. Schölkens*    Johann Wolfgang Goethe-Universität Frankfurt, Aventis Deutschland GmbH

*Prof. Dr. Jürgen Sandow*    Johann Wolfgang Goethe-Universität Frankfurt, Aventis Deutschland GmbH

*PD Dr. Günter Müller*    Ludwig Maximilian-Universität München, Institut für Genetik, Aventis Deutschland GmbH

*Dr. Wolfgang F. Vogel*    Assistant Professor, Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Canada



---

## Contributors

### List of contributors to the second edition

<i>Albus, Udo</i>	Aventis Pharma Research, D-65926 Frankfurt
<i>Bickel, Martin</i>	Aventis Pharma Research, Metabolism Research, D-65926 Frankfurt
<i>Bleich, Markus</i>	Aventis Pharma Research, Cardiovascular Research, D-65926 Frankfurt
<i>Dere, Ekrem</i>	Institute of Physiological Psychology, Heinrich Heine-Universität Düsseldorf
<i>Gögelein, Heinz</i>	Aventis Pharma Research, Cardiovascular Research, D-65926 Frankfurt
<i>Herling, Andreas W.</i>	Aventis Pharma Research, Metabolism Research, D-65926 Frankfurt
<i>Hropot, Max</i>	Aventis Pharma Research, Cardiovascular Research, D-65926 Frankfurt
<i>Laux, Volker</i>	Aventis Pharma Research, Cardiovascular Research, D-65926 Frankfurt
<i>Just, Melitta</i>	Aventis Pharma Research, Cardiovascular Research, D-65926 Frankfurt
<i>Müller, Günter</i>	Aventis Pharma Research, Metabolism Research, D-65926 Frankfurt
<i>Rieß, Günther</i>	Aventis Pharma Research, D-65926 Frankfurt
<i>Sadow, Jürgen</i>	Aventis Pharma Research, Metabolism Research, D-65926 Frankfurt
<i>Schäfer, Hans-Ludwig</i>	Aventis Pharma Research, Metabolism Research, D-65926 Frankfurt
<i>Vogel, Wolfgang F.</i>	Assistant Professor, Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Canada
<i>Vogel, Wolfgang H.</i>	Jefferson Medical College, Thomas Jefferson University, Department of Pharmacology, Philadelphia, USA
<i>Wirth, Klaus J.</i>	Aventis Pharma Research, Cardiovascular Research, D-65926 Frankfurt

**List of contributors to the first edition**

<i>Albus, Udo</i>	Hoechst-Marion-Roussel, Cardiovascular Research, D-65926 Frankfurt
<i>Bartlett, Robert R.</i>	Hoechst-Marion-Roussel, Immunopharmacology, D-65174 Wiesbaden
<i>Bickel, Martin</i>	Hoechst-Marion-Roussel, Metabolism Research, D-65926 Frankfurt
<i>Brioni, Jörge D.</i>	Abbott Laboratories, Neuroscience Research, Abbott Park, IL 60064 USA
<i>Gögelein, Heinz</i>	Hoechst-Marion-Roussel, Cardiovascular Research, D-65926 Frankfurt
<i>Greger, R.</i>	Institute of Physiology, University of Freiburg, D-79104 Freiburg
<i>Herling, Andreas W.</i>	Hoechst-Marion-Roussel, Metabolism Research, D-65926 Frankfurt
<i>Hock, Franz Jakob</i>	Hoechst-Marion-Roussel, General Pharmacology, D-65926 Frankfurt
<i>Hropot, Max</i>	Hoechst-Marion-Roussel, Cardiovascular Research, D-65926 Frankfurt
<i>Huger, Francis P.</i>	Hoechst-Marion-Roussel, Neuroscience Research, Sommerville, NJ, USA
<i>Jablonka, Bernd</i>	Hoechst-Marion-Roussel, Cardiovascular Research, D-65926 Frankfurt
<i>Just, Melitta</i>	Hoechst-Marion-Roussel, Cardiovascular Research, D-65926 Frankfurt
<i>Linz, Wolfgang</i>	Hoechst-Marion-Roussel, Cardiovascular Research, D-65926 Frankfurt
<i>Maas, Jochen</i>	Hoechst-Marion-Roussel, Preclinical Development, D-65926 Frankfurt
<i>McGaugh, James L.</i>	University of California at Irvine, Irvine, Ca 92717, USA
<i>Müller, Günter</i>	Hoechst-Marion-Roussel, Metabolism Research, D-65926 Frankfurt
<i>Raiss, Ruth X.</i>	Hoechst-Marion-Roussel, Osteoarthritis Research, D-65174 Wiesbaden
<i>v. Rechenberg, Wolfrad</i>	Hoechst-Marion-Roussel, Metabolism Research, D-65926 Frankfurt
<i>Rudolphi, Karl A.</i>	Hoechst-Marion-Roussel, Cardiovascular Research, D-65926 Frankfurt
<i>Schölkens, Bernward A.</i>	Hoechst-Marion-Roussel, Cardiovascular Research, D-65926 Frankfurt
<i>Seeger, Karl</i>	Hoechst-Marion-Roussel, Pharma Research, D-65926 Frankfurt
<i>Weithmann, K. U.</i>	Hoechst-Marion-Roussel, Immunopharmacology, D-65174 Wiesbaden
<i>Wirth, Klaus J.</i>	Hoechst-Marion-Roussel, Cardiovascular Research, D-65926 Frankfurt

---

# Contents

<b>Introduction</b>	
<b>Strategies in drug discovery and evaluation</b>	1
<b>0.1</b>	<b>Historical approaches in drug discovery</b> ..... 1
<b>0.2</b>	<b>Pharmacological approaches of modern medicine</b> ..... 2
<b>0.3</b>	<b>New approaches in drug discovery</b> ..... 3
0.3.1	Combinatorial chemistry ..... 6
0.3.2	High throughput screening, ultra high throughput screening, and high content screening ..... 7
0.3.3	Technologies for high throughput screening ..... 8
0.3.4	Pharmacogenomics ..... 14
0.3.5	Proteomics ..... 18
0.3.6	Array technology ..... 19
<b>0.4</b>	<b>Errors in screening procedures</b> ..... 20
<b>Chapter A</b>	
<b>Cardiovascular activity</b>	23
<b>A.1</b>	<b>Cardiovascular analysis</b> ..... 26
A.1.1	<i>In vitro</i> methods ..... 26
A.1.1.1	$\alpha_1$ -adrenoreceptor binding ..... 26
A.1.1.2	$\alpha_2$ -adrenoreceptor binding ..... 29
A.1.1.3	Electrically stimulated release of [ <sup>3</sup> H]norepinephrine from brain slices ..... 31
A.1.1.4	Imidazoline receptor binding ..... 33
A.1.1.5	$\beta$ -adrenoreceptor binding ..... 36
A.1.1.6	$\beta_1$ -adrenoreceptor binding ..... 38
A.1.1.7	$\beta_2$ -adrenoreceptor binding ..... 39
A.1.1.8	Adenosine A <sub>1</sub> receptor binding ..... 40
A.1.1.9	Adenosine A <sub>2</sub> receptor binding ..... 43
A.1.1.10	Adenosine A <sub>3</sub> receptor binding ..... 44
A.1.1.11	Inhibition of adenosine uptake in human erythrocytes ..... 45
A.1.1.12	Inhibition of the angiotensin-converting enzyme <i>in vitro</i> ..... 46
A.1.1.13	Quantitative autoradiographic localization of angiotensin-converting enzyme ..... 48
A.1.1.14	Angiotensin antagonism ..... 49
A.1.1.14.1	Angiotensin II receptor binding ..... 49
A.1.1.14.2	Angiotensin II induced contraction in isolated rabbit aorta ..... 52
A.1.1.14.3	Angiotensin II antagonism <i>in vivo</i> ..... 53
A.1.1.15	Renin-inhibitory activity using human kidney renin and a synthetic substrate ..... 55

---

A.1.1.16	PAF binding assay .....	57
A.1.1.17	Endothelin .....	58
A.1.1.17.1	General considerations .....	58
A.1.1.17.2	Evaluation of endothelin activity .....	59
A.1.1.17.3	Endothelin receptor antagonism <i>in vitro</i> .....	60
A.1.1.17.4	Endothelin receptor antagonism <i>in vivo</i> .....	61
A.1.1.17.5	Quantitative autoradiographic localization of endothelin-1 receptor ..	63
A.1.1.17.6	Inhibition of endothelin converting enzyme .....	63
A.1.1.18	Nitric oxide .....	66
A.1.1.18.1	General considerations on nitric oxide .....	66
A.1.1.18.2	Bioassay of EDRF release .....	67
A.1.1.18.3	Isolated arteries with and without endothelium .....	68
A.1.1.18.4	Nitric oxide formation by cultured endothelial cells .....	69
A.1.1.18.5	Expression of nitric oxide synthase .....	72
A.1.1.19	Inhibition of Na <sup>+</sup> /H <sup>+</sup> exchange .....	73
A.1.1.19.1	Inhibition of Na <sup>+</sup> /H <sup>+</sup> exchange in thrombocytes .....	75
A.1.1.19.2	Inhibition of Na <sup>+</sup> /H <sup>+</sup> exchange in cholesterol activated rabbit erythrocytes .....	75
A.1.1.19.3	Sodium influx into cultured cardiac myocytes .....	76
A.1.1.19.4	Inhibition of Na <sup>+</sup> /H <sup>+</sup> exchange into cultured aortic endothelial cells ..	76
A.1.1.19.5	NHE activity measured by intracellular pH in isolated ventricular myocytes .....	77
A.1.1.19.6	NHE subtype specificity .....	78
A.1.1.20	Inhibition of phosphodiesterase .....	79
A.1.1.21	Stimulation of heart membrane adenylate cyclase .....	80
A.1.1.22	<sup>3</sup> H-Forskolin binding assay .....	81
A.1.1.23	Patch clamp technique .....	83
A.1.1.23.1	Patch clamp technique in isolated cardiac myocytes .....	84
A.1.1.23.2	Voltage clamp studies on sodium channels .....	85
A.1.1.23.3	Voltage clamp studies on potassium channels .....	87
A.1.1.23.4	Voltage clamp studies on calcium channels .....	89
A.1.1.23.5	Patch clamp studies on chloride channels .....	92
A.1.1.24	Measurement of cytosolic calcium with fluorescent indicators ....	92
A.1.1.25	Measurement of contractile force of isolated cardiac myocytes ....	93
A.1.1.26	Adrenomedullin .....	94
A.1.1.26.1	General considerations .....	94
A.1.1.26.2	Receptor binding of adrenomedullin .....	96
A.1.1.27	Atrial natriuretic factor (ANF) .....	97
A.1.1.27.1	General considerations .....	97
A.1.1.27.2	Bioassay for ANF .....	98
A.1.1.27.3	Receptor binding of ANF .....	99
A.1.1.27.4	ANF gene expression .....	100
A.1.1.27.5	Radioimmunoassay for ANF .....	102
A.1.2	Studies in isolated organs .....	102
A.1.2.1	α-Sympatholytic activity in isolated vascular smooth muscle .....	102
A.1.2.2	α-Sympatholytic activity in the isolated guinea pig seminal vesicle ..	103
A.1.2.3	α-Sympatholytic activity in the isolated vas deferens of the rat ....	104
A.1.2.4	α-Sympatholytic activity in the isolated rat spleen .....	106
A.1.2.5	α-Sympatholytic activity in the isolated rat anococcygeus muscle ...	106
A.1.2.6	β <sub>1</sub> -Sympatholytic activity in isolated guinea pig atria .....	108
A.1.2.7	β <sub>2</sub> -Sympatholytic activity in the isolated tracheal chain .....	109
A.1.2.8	Angiotensin converting enzyme inhibition in the isolated guinea pig ileum .....	110
A.1.2.9	Contractile and relaxing activity on isolated blood vessels including effects of potassium channel openers .....	111

---

A.1.2.10	Isolated guinea pig ureter .....	115
A.1.2.11	Isolated corpus cavernosum .....	116
A.1.3	Cardiovascular analysis <i>in vivo</i> .....	118
A.1.3.1	Hemodynamic screening in anesthetized rats .....	118
A.1.3.2	Blood pressure in pithed rats .....	120
A.1.3.3	Antihypertensive vasodilator activity in ganglion-blocked, angiotensin II supported rats .....	121
A.1.3.4	Blood pressure in conscious hypertensive rats (tail cuff method) ..	122
A.1.3.5	Direct measurement of blood pressure in conscious rats with indwelling catheter .....	123
A.1.3.6	Cannulation techniques in rodents .....	125
A.1.3.6.1	Permanent cannulation of the jugular vein in rats .....	126
A.1.3.6.2	Permanent cannulation of the renal vein in rats .....	126
A.1.3.6.3	Permanent cannulation of the portal vein in rats .....	127
A.1.3.6.4	Permanent cannulation of the thoracic duct in rats .....	127
A.1.3.6.5	Portacaval anastomosis in rats .....	128
A.1.3.7	Cardiovascular analysis in anesthetized mice .....	129
A.1.3.8	Blood pressure in anesthetized cats .....	130
A.1.3.9	Cardiovascular drug challenging experiments in anesthetized dogs ..	131
A.1.3.10	Hemodynamic analysis in anaesthetized dogs .....	131
A.1.3.11	Hemodynamic measurements in conscious dogs .....	134
A.1.3.12	Hemodynamic studies in monkeys .....	135
A.1.3.13	Measurement of cardiac output and regional blood flow with microspheres .....	136
A.1.3.14	Carotid artery loop technique .....	137
A.1.3.15	Measurement of heart dimensions in anesthetized dogs .....	138
A.1.3.16	Telemetric monitoring of cardiovascular parameters in rats .....	139
A.1.3.17	Cardiovascular effects after intracerebroventricular administration .....	142
A.1.3.18	Influence on orthostatic hypotension .....	142
A.1.3.19	Bezold-Jarisch reflex .....	143
A.1.3.20	Endotoxin induced shock .....	145
A.1.3.21	Hemorrhagic shock .....	146
A.1.3.22	Tourniquet shock .....	147
A.1.3.23	Heat stroke .....	148
A.1.3.24	$\alpha$ - and $\beta$ -adrenoreceptors in the mouse iris .....	149
A.1.3.25	$\alpha_2$ -adrenoreceptor blockade measured <i>in vivo</i> by clonidine-induced sleep in chicks .....	151
A.1.3.26	Activity at $\beta_1$ - and $\beta_2$ -adrenoreceptors in the rat .....	151
A.1.3.27	$\beta_1$ - and $\beta_2$ -Sympatholytic activity in dogs .....	152
A.1.3.28	Intrinsic $\beta$ -sympathomimetic activity in reserpine-pretreated dogs ..	154
A.1.3.29	Cat nictitating membrane preparation (ganglion blocking activity) ..	154
A.1.3.30	Assessment of ganglion-blocking activity in the isolated bovine retractor penis muscle .....	156
A.1.3.31	Angiotensin II antagonism .....	158
A.1.3.32	ACE inhibition measured <i>in vivo</i> in the rat .....	161
A.1.3.33	Evaluation of renin inhibitors in dogs .....	162
A.1.3.34	Evaluation of renin inhibitors in monkeys .....	164
A.1.4	Cardiovascular safety studies .....	165
A.1.4.1	General considerations .....	165
A.1.4.2	Cardiovascular safety studies in dogs and other species .....	166
A.1.4.3	Monophasic action potentials in dogs .....	168
A.1.4.4	Studies of arrhythmogenic effects in isolated heart preparations ..	168
A.1.4.5	Studies in isolated Purkinje fibres .....	169
A.1.4.6	Studies in isolated ventricular myocytes .....	170

---

<b>A.2</b>	<b>Methods to induce experimental hypertension</b> .....	172
A.2.0.1	Acute renal hypertension in rats .....	172
A.2.0.2	Chronic renal hypertension in rats .....	172
A.2.0.3	Chronic renal hypertension in dogs .....	173
A.2.0.4	Neurogenic hypertension in dogs .....	174
A.2.0.5	DOCA-salt induced hypertension in rats .....	175
A.2.0.6	Fructose induced hypertension in rats .....	176
A.2.0.7	Genetic hypertension in rats .....	176
A.2.0.8	Pulmonary hypertension induced by monocrotaline .....	179
<b>A.3</b>	<b>Coronary drugs</b> .....	180
A.3.1	Isolated organs .....	180
A.3.1.1	Heart-lung preparation .....	180
A.3.1.2	Isolated heart according to LANGENDORFF .....	183
A.3.1.3	Coronary artery ligation in isolated working rat heart .....	188
A.3.1.4	Relaxation of bovine coronary artery .....	190
A.3.2	<i>In vivo</i> methods .....	191
A.3.2.1	Isoproterenol induced myocardial necrosis in rats .....	191
A.3.2.2	Myocardial infarction after coronary ligation .....	192
A.3.2.3	Occlusion of coronary artery in anesthetized dogs .....	194
A.3.2.4	Acute ischemia by injection of microspheres in dogs .....	196
A.3.2.5	Influence on myocardial preconditioning .....	198
A.3.3	<i>Ex vivo</i> methods .....	200
A.3.3.1	Plastic casts from coronary vasculature bed .....	200
<b>A.4</b>	<b>Calcium uptake inhibiting activity</b> .....	201
A.4.0.1	General considerations .....	201
A.4.1	<i>In vitro</i> methods .....	203
A.4.1.1	<sup>3</sup> H-nitrendipine binding <i>in vitro</i> .....	203
A.4.2	Isolated organs .....	203
A.4.2.1	Calcium antagonism on action potential of isolated guinea pig papillary muscle .....	205
A.4.2.2	Calcium antagonism in the isolated guinea pig atrium .....	206
A.4.2.3	Calcium antagonism in the isolated rabbit aorta .....	207
A.4.2.4	Calcium antagonism in the isolated guinea pig pulmonary artery .....	208
A.4.3	<i>In vivo</i> methods .....	209
A.4.3.1	Evaluation of calcium blockers in the pithed rat .....	209
<b>A.5</b>	<b>Anti-arrhythmic activity</b> .....	209
A.5.0.1	General considerations .....	209
A.5.0.2	Electrocardiography in animals .....	211
A.5.0.3	Aconitine antagonism in rats .....	213
A.5.0.4	Digoxin-induced ventricular arrhythmias in anesthetized guinea pigs .....	215
A.5.0.5	Strophanthin or ouabain induced arrhythmia .....	215
A.5.0.6	Ventricular fibrillation electrical threshold .....	216
A.5.0.7	Coronary artery ligation, reperfusion arrhythmia and infarct size in rats .....	217
A.5.0.8	Ventricular arrhythmia after coronary occlusion .....	220
A.5.0.8.1	Ventricular fibrillation after coronary occlusion and reperfusion in anesthetized dogs .....	220
A.5.0.8.2	Harris dog model of ventricular tachycardia .....	222
A.5.0.8.3	Protection against sudden coronary death .....	223
A.5.0.8.4	Ventricular fibrillation induced by cardiac ischemia during exercise .....	224



---

A.5.0.9	Characterization of anti-arrhythmic activity in the isolated right ventricular guinea pig papillary muscle .....	226
A.5.0.10	Action potential and refractory period in isolated left ventricular guinea pig papillary muscle .....	227
<b>A.6</b>	<b>Methods to induce cardiac hypertrophy and insufficiency</b> .....	229
A.6.0.1	Aortic banding in rats .....	229
A.6.0.2	Cardiac hypertrophy in mice .....	231
A.6.0.3	Cardiac insufficiency in guinea pigs .....	231
A.6.0.4	Cardiomyopathic Syrian hamster .....	233
A.6.0.5	Hypertrophy of cultured cardiac cells .....	234
<b>A.7</b>	<b>Positive inotropic activity (cardiac glycosides)</b> .....	235
A.7.0.1	General considerations .....	235
A.7.1	<i>In vitro</i> tests .....	236
A.7.1.1	Ouabain binding .....	236
A.7.1.2	Influence on Na <sup>+</sup> /K <sup>+</sup> ATPase .....	237
A.7.2	Tests in isolated tissues and organs .....	238
A.7.2.1	Isolated cat papillary muscle .....	238
A.7.2.2	Isolated hamster cardiomyopathic heart .....	239
A.7.2.3	Potassium loss from the isolated guinea pig heart .....	240
A.7.3	<i>In vivo</i> tests .....	241
A.7.3.1	Cardiac toxicity in cats (Hatcher's method) .....	241
A.7.3.2	Decay rate and enteral absorption rate of cardiac glycosides .....	241
<b>A.8</b>	<b>Effects on blood supply and on arterial and venous tonus</b> .....	242
A.8.1	Models for stroke and multi-infarct cerebral dysfunction .....	242
A.8.1.1	Cerebral ischemia by carotid artery occlusion in Mongolian gerbils .....	242
A.8.1.2	Forebrain ischemia in rats .....	244
A.8.1.3	Hypoxia tolerance test in rats .....	245
A.8.1.4	Middle cerebral artery occlusion in rats .....	246
A.8.1.5	Photochemically induced focal cerebral ischemia in rats .....	249
A.8.1.6	Microdialysis and neuroprotection experiments after global ischemia in rats .....	250
A.8.1.7	Hypoxia/hypoglycemia in hippocampal slices .....	251
A.8.1.8	Measurement of local cerebral blood flow and glucose utilization in rats .....	252
A.8.1.9	Cerebrovascular resistance in anesthetized baboons .....	253
A.8.1.10	Effect on cerebral blood flow in cats (Fluovography) .....	255
A.8.1.11	Effect on cerebral blood flow and in ischemic skeletal muscle in rats (Laser-Doppler-Effect) .....	256
A.8.1.12	Traumatic brain injury .....	257
A.8.2	Peripheral blood supply .....	259
A.8.2.1	Perfused hindquarter preparation with sympathetic nerve stimulation in rats .....	259
A.8.2.2	Effect on peripheral blood flow in rats .....	261
A.8.2.3	Effect on peripheral blood flow in anesthetized dogs .....	262
A.8.2.4	Effect on peripheral blood supply measured by local oxygen pressure .....	263
A.8.2.5	Effect on mesenteric blood flow in rats .....	264
A.8.2.6	Effect on pulmonary blood flow .....	266
A.8.2.7	Effect on contractile force of ischemic muscle .....	267
A.8.2.8	Effect on perfusion of rabbit ear (Pissemki method) .....	268
A.8.2.9	Effect on venous tonus <i>in situ</i> in dogs .....	270

A.8.3	Angiogenesis and anti-angiogenesis .....	270
A.8.3.1	General considerations .....	270
A.8.3.2	Endothelial cell proliferation .....	271
A.8.3.3	Chorioallantoic membrane assay .....	272
A.8.3.4	Cornea neovascularization .....	273
A.8.3.5	Rat subcutaneous air sac model .....	275
A.8.3.6	Mesenteric window angiogenesis model .....	276

## Chapter B

### Activity on blood constituents .....

<b>B.1</b>	<b><i>In vitro</i> tests</b> .....	277
B.1.1	Blood coagulation tests .....	277
B.1.2	Thrombelastography .....	278
B.1.3	Chandler loop .....	280
B.1.4	Platelet aggregation and deaggregation in platelet rich plasma or washed platelets (BORN method) .....	280
B.1.5	Platelet aggregation after gel filtration .....	282
B.1.6	Platelet aggregation in whole blood .....	283
B.1.7	Euglobulin lysis time .....	284
B.1.8	Fibrinogen receptor binding .....	285
B.1.9	PAF antagonism .....	286
B.1.10	Flow behavior of erythrocytes .....	287
B.1.11	Filterability of erythrocytes .....	287
B.1.12	Erythrocyte aggregation .....	288
B.1.13	Determination of plasma viscosity .....	289
<b>B.2</b>	<b><i>In vivo</i> or <i>ex vivo</i> models</b> .....	289
B.2.1	Stenosis- and mechanical injury-induced coronary thrombosis (Folts-model) .....	290
B.2.2	Stenosis-and mechanical injury-induced arterial and venous thrombosis (Harbauer-model) .....	294
B.2.3	Electrical-induced thrombosis .....	296
B.2.4	FeCl <sub>3</sub> -induced thrombosis .....	297
B.2.5	Laser-induced thrombosis .....	298
B.2.6	Photochemical-induced thrombosis .....	299
B.2.7	Foreign-surface thrombosis .....	299
B.2.7.1	Wire-coil induced thrombosis .....	299
B.2.7.2	Eversion-graft induced thrombosis .....	300
B.2.7.3	Arterio-venous shunt thrombosis .....	301
B.2.7.4	Thread-induced venous thrombosis .....	302
B.2.7.5	Thrombus formation on superfused tendon .....	303
B.2.8	Stasis-induced thrombosis (Wessler-model) .....	303
B.2.9	Experimental thrombocytopenia or leucocytopenia .....	305
B.2.10	Collagenase-induced thrombocytopenia .....	306
B.2.11	Reversible intravital aggregation of platelets .....	306
<b>B.3</b>	<b>Bleeding models</b> .....	307
B.3.1	Subaqueous tail bleeding time in rodents .....	307
B.3.2	Arterial bleeding time in mesentery .....	308
B.3.3	Template Bleeding Time Method .....	308
<b>B.4</b>	<b>Genetically modified animals</b> .....	309
B.4.1	Knock out mice .....	309

<b>Chapter C</b>		
<b>Activity on urinary tract</b>		317
<b>C.1 Diuretic and saluretic activity</b>		317
C.1.1 <i>In vitro</i> methods		317
C.1.1.1 Carbonic anhydrase inhibition <i>in vitro</i>		317
C.1.1.2 Patch clamp technique in kidney cells		319
C.1.1.3 Perfusion of isolated kidney tubules		320
C.1.1.4 Isolated perfused kidney		322
C.1.2 <i>In vivo</i> methods		323
C.1.2.1 Diuretic activity in rats (LIPSCHITZ test)		323
C.1.2.2 Saluretic activity in rats		324
C.1.2.3 Diuretic and saluretic activity in dogs		325
C.1.2.4 Clearance methods		326
C.1.2.5 Micropuncture techniques in the rat		327
C.1.2.6 Stop-flow technique		328
<b>C.2 Impaired renal function</b>		328
C.2.1 Chronic renal failure in the rat		328
C.2.2 Chronic renal failure after subtotal (five-sixths) nephrectomy in rats		329
C.2.3 Experimental nephritis		333
C.2.3.1 General considerations		333
C.2.3.2 Nephrotoxic serum nephritis		333
C.2.4 Experimental nephrosis		336
<b>C.3 Uricosuric and hypo-uricemic activity</b>		337
C.3.1 <i>In vitro</i> methods		337
C.3.1.1 Inhibition of xanthine oxidase <i>in vitro</i> indicating hypouricemic activity		337
C.3.1.2 Urate uptake in brush border membrane vesicles		337
C.3.2 <i>In vivo</i> methods		338
C.3.2.1 Diuretic and uricosuric activity in mice		338
C.3.2.2 Hypouricemic activity after allantoxanamide treatment in rats		339
C.3.2.3 Hypouricemic and uricosuric activity after potassium oxonate treatment in rats		339
C.3.2.4 Phenol red excretion in rats		340
C.3.2.5 Uricosuric activity in Dalmatian dogs		340
C.3.2.6 Uricosuric activity in Cebus monkeys		341
<b>C.4 Influence on lower urinary tract</b>		342
C.4.1 <i>In vivo</i> studies		342
C.4.1.1 Micturition studies		342
C.4.2 Studies in isolated organs		344
C.4.2.1 Studies on renal pelvis		344
C.4.2.2 Studies on urinary bladder and internal urethral sphincter		345
C.4.2.3 Effects on external urethral sphincter		348
C.4.2.4 Propagation of impulses in the guinea pig ureter		348
<b>Chapter D</b>		
<b>Respiratory activity</b>		351
<b>D.1 <i>In vitro</i> tests</b>		351
D.1.0.1 Histamine (H <sub>1</sub> ) receptor binding		352

---

<b>D.2</b>	<b>Effects on air ways</b> .....	352
D.2.1	Tests in isolated organs .....	352
D.2.1.1	Spasmolytic activity in isolated guinea pig lung strips .....	352
D.2.1.2	Spasmolytic activity in isolated trachea .....	353
D.2.1.3	Reactivity of the isolated perfused trachea .....	355
D.2.1.4	Bronchial perfusion of isolated lung .....	357
D.2.1.5	Vascular and airway responses in the isolated lung .....	357
D.2.2	<i>In vivo</i> tests .....	359
D.2.2.1	Bronchospasmolytic activity in anesthetized guinea pigs (Konzett-Rössler method) .....	359
D.2.2.2	Effect of arachidonic acid or PAF on respiratory function <i>in vivo</i> .....	361
D.2.2.3	Bronchial hyperreactivity .....	362
D.2.2.4	Body plethysmography and respiratory parameters after histamine-induced bronchoconstriction in anesthetized guinea pigs .....	364
D.2.2.5	Pneumotachography in anesthetized guinea pigs .....	366
D.2.2.6	Airway microvascular leakage .....	368
D.2.2.7	Isolated larynx <i>in situ</i> .....	369
D.2.2.8	Safety pharmacology of the respiratory system .....	370
D.2.2.8.1	Effects of respiratory depressant drugs in conscious rats .....	371
D.2.2.8.2	Pulmonary function in unanesthetized dogs .....	372
<b>D.3</b>	<b>Antitussive activity</b> .....	373
D.3.0.1	Antitussive activity after irritant inhalation in guinea pigs .....	373
D.3.0.2	Cough induced by mechanical stimulation .....	374
D.3.0.3	Cough induced by stimulation of the nervus laryngicus superior ..	375
<b>D.4</b>	<b>Effects on tracheal cells and bronchial mucus secretion and transport</b> .....	376
D.4.0.1	<i>In vitro</i> studies of mucus secretion .....	376
D.4.0.2	Acute studies of mucus secretion .....	377
D.4.0.3	Studies of mucus secretion with chronic cannulation .....	378
D.4.0.4	Bronchoalveolar lavage .....	379
D.4.0.5	Ciliary activity .....	380
D.4.0.6	Studies of mucociliary transport .....	381
D.4.0.7	Culture of tracheal epithelial cells .....	383
 <b>Chapter E</b>		
<b>Psychotropic and neurotropic activity</b> .....		385
<b>E.1</b>	<b>Effects on behavior and muscle coordination</b> .....	388
E.1.1	Spontaneous behavior .....	388
E.1.1.1	General considerations .....	388
E.1.1.2	Observational assessment .....	388
E.1.1.3	Safety pharmacology core battery .....	389
E.1.2	Effects on motility (sedative or stimulatory activity) .....	390
E.1.2.1	General considerations .....	390
E.1.2.2	Method of intermittent observations .....	390
E.1.2.3	Open field test .....	391
E.1.2.4	Hole-board test .....	393
E.1.2.5	Combined open field test .....	394
E.1.2.6	EEG analysis from rat brain by telemetry .....	395
E.1.3	Tests for muscle coordination .....	396

---

E.1.3.1	Inclined plane .....	396
E.1.3.2	Chimney test .....	396
E.1.3.3	Grip strength .....	397
E.1.3.4	Rotarod method .....	398
E.1.3.5	Influence on polysynaptic reflexes .....	398
E.1.3.6	Masticatory muscle reflexes .....	400
<b>E.2</b>	<b>Tests for anxiolytic activity</b> .....	<b>401</b>
E.2.0.1	General considerations .....	401
E.2.1	<i>In vitro</i> methods .....	402
E.2.1.1	<i>In vitro</i> assay for GABAergic compounds: [ <sup>3</sup> H]-GABA receptor binding .....	402
E.2.1.2	GABA <sub>A</sub> receptor binding .....	403
E.2.1.3	GABA <sub>B</sub> receptor binding .....	406
E.2.1.4	Benzodiazepine receptor: [ <sup>3</sup> H]-flunitrazepam binding assay .....	408
E.2.1.5	Serotonin receptor binding .....	410
E.2.1.5.1	General considerations .....	410
E.2.1.5.2	Serotonin (5HT <sub>1A</sub> ) receptor: binding of [ <sup>3</sup> H]-8-hydroxy-2-(di-n-propylamino)-tetralin ([ <sup>3</sup> H]-DPAT) .....	414
E.2.1.5.3	Serotonin (5HT <sub>1B</sub> ) receptors in brain: binding of [ <sup>3</sup> H]5-hydroxytryptamine ([ <sup>3</sup> H]5HT) .....	417
E.2.1.5.4	5HT <sub>3</sub> receptor in rat entorhinal cortex membranes: binding of [ <sup>3</sup> H]GR 65630 .....	419
E.2.1.6	Histamine H <sub>3</sub> receptor binding in brain .....	421
E.2.2	Anticonvulsant activity .....	422
E.2.2.1	Pentylentetrazole (Metrazol) induced convulsions .....	422
E.2.2.2	Strychnine-induced convulsions .....	423
E.2.2.3	Picrotoxin-induced convulsions .....	424
E.2.2.4	Isoniazid-induced convulsions .....	424
E.2.2.5	Yohimbine-induced convulsions .....	425
E.2.3	Anti-aggressive activity .....	425
E.2.3.1	Foot-shock induced aggression .....	425
E.2.3.2	Isolation-induced aggression .....	426
E.2.3.3	Resident-intruder aggression test .....	427
E.2.3.4	Water competition test .....	428
E.2.3.5	Maternal aggression in rats .....	428
E.2.3.6	Rage reaction in cats .....	430
E.2.4	Effects on behavior .....	430
E.2.4.1	Anti-anxiety test (light-dark model) .....	430
E.2.4.2	Anticipatory anxiety in mice .....	431
E.2.4.3	Social interaction in rats .....	432
E.2.4.4	Elevated plus maze test .....	434
E.2.4.5	Water maze test .....	435
E.2.4.6	Staircase test .....	436
E.2.4.7	Cork gnawing test in the rat .....	437
E.2.4.8	Distress vocalization in rat pups .....	437
E.2.4.9	Schedule induced polydipsia in rats .....	438
E.2.4.10	Four plate test in mice .....	439
E.2.4.11	Footshock induced freezing behavior in rats .....	439
E.2.4.12	Experimental anxiety in mice .....	440
E.2.4.13	mCPP induced anxiety in rats .....	441
E.2.4.14	Acoustic startle response in rats .....	442
E.2.4.15	Unconditioned conflict procedure (Vogel test) .....	443
E.2.4.16	Novelty-suppressed feeding .....	444
E.2.4.17	Shock probe conflict procedure .....	445

---

E.2.4.18	Ultrasound induced defensive behavior in rats	445
E.2.4.19	Anxiety/defense test battery in rats	446
E.2.4.20	Marmoset human threat test	447
E.2.4.21	Aversive brain stimulation	448
E.2.5	Conditioned behavioral responses	450
E.2.5.1	Sidman avoidance paradigm	450
E.2.5.2	Geller conflict paradigm	451
E.2.5.3	Conditioned defensive burying in rats	453
E.2.5.4	Taste aversion paradigm	454
E.2.6	Effects on the endocrine system	456
E.2.6.1	Plasma catecholamine levels during and after stress	456
E.2.6.2	Plasma corticosterone levels influenced by psychotropic drugs	457
E.2.7	Benzodiazepine dependence	458
E.2.7.1	General considerations	458
E.2.7.2	Benzodiazepine tolerance and dependence in rats	458
<b>E.3</b>	<b>Anti-epileptic activity</b>	459
E.3.0.1	General considerations	459
E.3.1	<i>In vitro</i> methods	460
E.3.1.1	<sup>3</sup> H-GABA receptor binding	460
E.3.1.2	GABA <sub>A</sub> receptor binding	460
E.3.1.3	GABA <sub>B</sub> receptor binding	460
E.3.1.4	<sup>3</sup> H-GABA uptake in rat cerebral cortex synaptosomes	461
E.3.1.5	GABA uptake and release in rat hippocampal slices	462
E.3.1.6	Glutamate receptors: [ <sup>3</sup> H]CPP binding	463
E.3.1.7	NMDA receptor complex: [ <sup>3</sup> H]TCP binding	466
E.3.1.8	Metabotropic glutamate receptors	470
E.3.1.9	Excitatory amino acid transporters	473
E.3.1.10	[ <sup>35</sup> S]TBPS binding in rat cortical homogenates and sections	474
E.3.1.11	[ <sup>3</sup> H]glycine binding in rat cerebral cortex	476
E.3.1.12	[ <sup>3</sup> H]strychnine sensitive glycine receptor	478
E.3.1.13	Electrical recordings from hippocampal slices <i>in vitro</i>	479
E.3.1.14	Electrical recordings isolated brain cells	481
E.3.1.15	Isolated neonatal rat spinal cord	482
E.3.1.16	Cell culture of neurons	484
E.3.2	<i>In vivo</i> methods	487
E.3.2.1	Electroshock in mice	487
E.3.2.2	Pentylenetetrazol test in mice and rats	487
E.3.2.3	Strychnine-induced convulsions in mice	487
E.3.2.4	Picrotoxin-induced convulsions in mice	488
E.3.2.5	Isoniazid-induced convulsions in mice	488
E.3.2.6	Bicuculline test in rats	488
E.3.2.7	4-aminopyridine-induced seizures in mice	488
E.3.2.8	Epilepsy induced by focal lesions	489
E.3.2.9	Kindled rat seizure model	491
E.3.2.10	Posthypoxic myoclonus in rats	492
E.3.2.11	Genetic animal models of epilepsy	493
<b>E.4</b>	<b>Hypnotic activity</b>	495
E.4.0.1	General considerations	495
E.4.1	<i>In vivo</i> methods	495
E.4.1.1	Potentiation of hexobarbital sleeping time	495
E.4.1.2	Experimental insomnia in rats	496
E.4.1.3	EEG registration in conscious cats	497
E.4.1.4	Automated rat sleep analysis system	499

<b>E.5</b>	<b>Neuroleptic activity</b> .....	500
E.5.0.1	General considerations .....	500
E.5.1	<i>In vitro</i> methods .....	500
E.5.1.1	D <sub>1</sub> Receptor assay: [ <sup>3</sup> H]-SCH 23390 binding to rat striatal homogenates .....	500
E.5.1.2	D <sub>2</sub> Receptor assay: [ <sup>3</sup> H]-spiperidol binding .....	502
E.5.1.3	Dopamine D <sub>2</sub> receptor autoradiography ( <sup>3</sup> H-Spiperone binding) ..	504
E.5.1.4	Binding to the D <sub>3</sub> receptor .....	506
E.5.1.5	Binding to D <sub>4</sub> receptors .....	507
E.5.1.6	Determination of dopamine autoreceptor activity .....	509
E.5.1.7	Dopamine-sensitive adenylate cyclase in rat striatum .....	510
E.5.1.8	α <sub>1</sub> -adrenergic receptor binding in brain .....	511
E.5.1.9	[ <sup>3</sup> H]Spiperidol binding to 5HT <sub>2</sub> receptors in rat cerebral cortex ...	512
E.5.1.10	Serotonin 5HT <sub>2</sub> receptor autoradiography ( <sup>3</sup> H-Spiperone binding) ..	514
E.5.1.11	Binding to the sigma receptor .....	516
E.5.1.12	Simultaneous determination of norepinephrine, dopamine, DOPAC, HVA, HIAA, and 5-HT from rat brain areas .....	518
E.5.1.13	Measurement of neurotransmitters by intracranial microdialysis ..	519
E.5.1.14	Use of push-pull cannulae to determine the release of endogenous neurotransmitters .....	522
E.5.1.15	Fos protein expression in brain .....	524
E.5.1.16	Neurotensin .....	525
E.5.1.16.1	General considerations on neurotensin and neurotensin receptors ....	525
E.5.1.16.2	Neurotensin receptor binding .....	527
E.5.2	Behavioral tests .....	529
E.5.2.1	Golden hamster test .....	529
E.5.2.2	Influence on behavior of the cotton rat .....	530
E.5.2.3	Artificial hibernation in rats .....	531
E.5.2.4	Catalepsy in rodents .....	531
E.5.2.5	Pole climb avoidance in rats .....	532
E.5.2.6	Foot-shock induced aggression .....	533
E.5.2.7	Brain self stimulation .....	533
E.5.3	Tests based on the mechanism of action .....	534
E.5.3.1	Amphetamine group toxicity .....	534
E.5.3.2	Inhibition of amphetamine stereotypy in rats .....	535
E.5.3.3	Inhibition of apomorphine climbing in mice .....	536
E.5.3.4	Inhibition of apomorphine stereotypy in rats .....	537
E.5.3.5	Yawning/penile erection syndrome in rats .....	538
E.5.3.6	Inhibition of mouse jumping .....	540
E.5.3.7	Antagonism against MK-801 induced locomotion and falling in mice .....	540
E.5.3.8	Inhibition of apomorphine-induced emesis in the dog .....	541
E.5.3.9	Purposeless chewing in rats .....	541
E.5.3.10	Single unit recording of A9 and A10 midbrain dopaminergic neurons .....	542
E.5.3.11	<i>In vivo</i> voltammetry .....	543
<b>E.6</b>	<b>Antidepressant activity</b> .....	545
E.6.0.1	General considerations .....	545
E.6.1	<i>In vitro</i> methods .....	546
E.6.1.1	Inhibition of [ <sup>3</sup> H]-norepinephrine uptake in rat brain synaptosomes .....	546
E.6.1.2	Inhibition of [ <sup>3</sup> H]-dopamine uptake in rat striatal synaptosomes ..	546
E.6.1.3	Inhibition of [ <sup>3</sup> H]-serotonin uptake in synaptosomes .....	548
E.6.1.4	Binding to monoamine transporters .....	549



---

E.6.1.5	Antagonism of p-chloramphetamine toxicity by inhibitors of serotonin uptake .....	551
E.6.1.6	Receptor subsensitivity after treatment with antidepressants .....	552
E.6.1.7	Measurement of $\beta$ -adrenoreceptor stimulated adenylate cyclase ..	554
E.6.1.8	[ <sup>3</sup> H]Yohimbine binding to $\alpha_2$ -adrenoceptors in rat cerebral cortex .....	555
E.6.1.9	Test for anticholinergic properties by [ <sup>3</sup> H]-QNB binding to muscarinic cholinergic receptors in rat brain .....	556
E.6.1.10	Monoamine oxidase inhibition: Inhibition of type A and type B monoamine oxidase activities in rat brain synaptosomes .....	557
E.6.2	Behavioral tests .....	558
E.6.2.1	Catalepsy antagonism in chicken .....	558
E.6.2.2	Despair swim test .....	559
E.6.2.3	Tail suspension test in mice .....	561
E.6.2.4	Learned helplessness in rats .....	561
E.6.2.5	Muricide behavior in rats .....	562
E.6.2.6	Behavioral changes after neonatal clomipramine treatment .....	563
E.6.2.7	Antidepressant-like activity in differential-reinforcement of low rate 72-second schedule .....	565
E.6.3	Tests for antidepressant activity based on the mechanism of action .....	566
E.6.3.1	Potentialiation of norepinephrine toxicity .....	566
E.6.3.2	Compulsive gnawing in mice .....	567
E.6.3.3	Apomorphine- induced hypothermia in mice .....	567
E.6.3.4	Tetrabenazine antagonism in mice .....	568
E.6.3.5	Reserpine induced hypothermia .....	569
E.6.3.6	5-Hydroxytryptophan potentiation in mice .....	570
E.6.3.7	5-Hydroxytryptophan potentiation in rats .....	571
E.6.3.8	Yohimbine toxicity enhancement .....	571
E.6.3.9	Tryptamine seizure potentiation in rats .....	572
E.6.3.10	Serotonin syndrome in rats .....	572
E.6.3.11	Hypermotility in olfactory-bulbectomized rats .....	574
E.6.3.12	Sexual behavior in male rats .....	575
<b>E.7</b>	<b>Anti-Parkinsonism activity</b> .....	<b>577</b>
E.7.0.1	General considerations .....	577
E.7.1	<i>In vivo</i> methods .....	577
E.7.1.1	Tremorine and oxotremorine antagonism .....	577
E.7.1.2	MPTP model in monkeys .....	579
E.7.1.3	Reserpine antagonism .....	580
E.7.1.4	Circling behavior in nigrostriatal lesioned rats .....	581
E.7.1.5	Elevated body swing test .....	583
E.7.1.6	Skilled paw reaching in rats .....	583
E.7.1.7	Stepping test in rats .....	585
<b>E.8</b>	<b>General anesthesia</b> .....	<b>586</b>
E.8.1	Intravenous anesthesia .....	586
E.8.1.1	General considerations .....	586
E.8.1.2	Screening of intravenous anesthetics .....	587
E.8.1.3	EEG threshold test in rats .....	588
E.8.1.4	Efficacy and safety of intravenous anesthetics .....	589
E.8.2	Inhalation anesthesia .....	589
E.8.2.1	General considerations .....	589
E.8.2.2	Screening of volatile anesthetics .....	590
E.8.2.3	Efficacy and safety of inhalation anesthetics .....	591



<b>Chapter F</b>		
<b>Drug effects on learning and memory</b> .....		595
<b>F.1</b>	<b>Introduction</b> .....	595
<b>F.2</b>	<b><i>In vitro</i> methods</b> .....	599
F.2.0.1	<i>In vitro</i> inhibition of acetylcholine-esterase activity in rat striatum ..	599
F.2.0.2	<i>In vitro</i> inhibition of butyrylcholine-esterase activity in human serum .	601
F.2.0.3	<i>Ex vivo</i> cholinesterase inhibition .....	601
F.2.0.4	Molecular forms of acetylcholinesterase from rat frontal cortex and striatum .....	603
F.2.0.5	Release of [ <sup>3</sup> H]ACh and other transmitters from rat brain slices ..	605
F.2.0.6	[ <sup>3</sup> H]oxotremorine-M binding to muscarinic cholinergic receptors in rat forebrain .....	608
F.2.0.7	[ <sup>3</sup> H]-N-methylscopolamine binding in the presence and absence of Gpp(NH)p .....	610
F.2.0.8	Stimulation of phosphatidylinositol turnover in rat brain slices ....	611
F.2.0.9	[ <sup>3</sup> H]-N-methylcarbamylcholine binding to nicotinic cholinergic receptors in rat frontal cortex .....	613
F.2.0.10	Cultured neurons/astroglial cells .....	615
F.2.0.11	Inhibition of respiratory burst in microglial cells/macrophages ....	618
<b>F.3</b>	<b><i>In vivo</i> methods</b> .....	619
F.3.1	Inhibitory (passive) avoidance .....	619
F.3.1.1	Step-down .....	619
F.3.1.2	Step-through .....	620
F.3.1.3	Two compartment test .....	621
F.3.1.4	Up-hill avoidance .....	621
F.3.1.5	Trial-to-criteria inhibitory avoidance .....	622
F.3.1.6	Scopolamine-induced amnesia in mice .....	623
F.3.1.7	Memory impairment by basal forebrain lesions in rats .....	624
F.3.1.8	Ischemia-induced amnesia in gerbils .....	624
F.3.1.9	Cognitive deficits on chronic low dose MPTP-treated monkeys ...	625
F.3.2	Active avoidance .....	626
F.3.2.1	Runway avoidance .....	626
F.3.2.2	Shuttle box avoidance (two-way shuttle box) .....	627
F.3.2.3	Jumping avoidance (one-way shuttle box) .....	627
F.3.3	Discrimination learning .....	628
F.3.3.1	Spatial habituation learning .....	628
F.3.3.2	Spatial discrimination .....	629
F.3.3.3	Spatial learning in the radial arm maze .....	630
F.3.3.4	Visual discrimination .....	631
F.3.3.5	Spatial learning in the water maze .....	632
F.3.3.6	Olfactory learning .....	633
F.3.3.7	Aversive discrimination in chickens .....	634
F.3.4	Conditioned responses .....	636
F.3.4.1	Conditioned nictitating membrane response in rabbits .....	636
F.3.4.2	Automated learning and memory model in mice .....	637
F.3.5	Studies in aged monkeys .....	639
F.3.6	Electrophysiological methods .....	639
F.3.6.1	Long-term potentiation in hippocampal slices .....	639
F.3.6.2	Long term potentiation <i>in vivo</i> .....	641
F.3.6.3	Long latency averaged potentials .....	642
F.3.7	Metabolic influence .....	643
F.3.7.1	Sodium nitrite intoxication (NaNO <sub>2</sub> ) .....	643

**Chapter G****Effects on peripheral nerve function** ..... 645

<b>G.1</b>	<b>Local anesthetic activity</b> .....	645
G.1.0.1	General considerations .....	645
G.1.1	Conduction anesthesia .....	646
G.1.1.1	Conduction anesthesia in the sciatic nerve of the frog .....	646
G.1.1.2	Conduction anesthesia in the sciatic nerve of the rat .....	647
G.1.1.3	Conduction anesthesia on the mouse tail .....	648
G.1.1.4	Rabbit tooth pulp assay .....	649
G.1.1.5	Retrolubular block in dogs .....	650
G.1.1.6	Isolated sciatic nerve preparation of the frog .....	650
G.1.1.7	Isolated mammalian sciatic nerve preparation .....	652
G.1.1.8	Effect of local anesthetics on different nerve fibres .....	653
G.1.1.9	Measurement of sodium and potassium conductance in voltage clamp experiments .....	654
G.1.2	Infiltration anesthesia .....	655
G.1.2.1	Infiltration anesthesia in guinea pig's wheals .....	655
G.1.3	Surface anesthesia .....	655
G.1.3.1	Surface anesthesia on the cornea of rabbits .....	655
G.1.3.2	Suppression of sneezing reflex in rabbits .....	656
G.1.4	Epidural anesthesia .....	657
G.1.4.1	Epidural anesthesia in guinea pigs .....	657
G.1.5	Intrathecal (spinal) anesthesia .....	658
G.1.5.1	Spinal anesthesia in rats .....	658
G.1.5.2	Blockade of urethral reflex in rabbits .....	660
G.1.6	Endoanesthetic effect .....	660
G.1.7	Effect on electroretinogram .....	662
<b>G.2</b>	<b>Neuromuscular blocking activity</b> .....	663
G.2.0.1	General considerations .....	663
G.2.0.2	Isolated phrenic nerve diaphragm preparation of the rat .....	664
G.2.0.3	Sciatic nerve-gastrocnemius muscle preparation in the rabbit .....	666
G.2.0.4	Evaluation of neuromuscular blockade in anesthetized mice .....	668

**Chapter H****Analgesic, anti-inflammatory, and anti-pyretic activity** ..... 669

<b>H.1</b>	<b>Central analgesic activity</b> .....	670
H.1.0.1	General considerations .....	670
H.1.1	<i>In vitro</i> methods for central analgesic activity .....	671
H.1.1.1	Survey .....	671
H.1.1.2	<sup>3</sup> H-Naloxone binding assay .....	674
H.1.1.3	<sup>3</sup> H-Dihydromorphine binding to $\mu$ opiate receptors in rat brain ...	675
H.1.1.4	<sup>3</sup> H-Bremazocine binding to $\kappa$ opiate receptors in guinea pig cerebellum .....	676
H.1.1.5	Inhibition of enkephalinase .....	677
H.1.1.6	Nociceptin .....	678
H.1.1.6.1	General considerations on nociceptin .....	678
H.1.1.6.2	Receptor binding of nociceptin .....	679
H.1.1.6.3	Bioassays for nociceptin .....	681
H.1.1.7	Vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) .....	682
H.1.1.8	Cannabinoid activity .....	684

---

H.1.1.8.1	General considerations on cannabinoids	684
H.1.1.8.2	Receptor binding of cannabinoids	686
H.1.1.9	Vanilloid (capsaicin) activity	688
H.1.1.9.1	General considerations on vanilloids	688
H.1.1.9.2	Vanilloid receptor binding	690
H.1.1.9.3	Evaluation of vanilloid receptor antagonists	691
H.1.2	<i>In vivo</i> methods for testing central analgesic activity	692
H.1.2.1	General considerations	692
H.1.2.2	HAFFNER's tail clip method	693
H.1.2.3	Radiant heat method	694
H.1.2.4	Hot plate method	696
H.1.2.5	Tail immersion test	697
H.1.2.6	Electrical stimulation of the tail	698
H.1.2.7	Grid shock test	699
H.1.2.8	Tooth pulp stimulation	700
H.1.2.9	Monkey shock titration test	702
H.1.2.10	Formalin test in rats	702
H.1.2.11	Experimental neuropathy	704
H.1.3	Side effects of central analgesic drugs	706
H.1.3.1	General considerations	706
H.1.3.2	Test for respiratory depression	706
H.1.3.3	Decrease of body temperature	707
H.1.3.4	Methods for the study of tolerance	707
H.1.3.5	Tests for physical dependence	708
H.1.3.6	Tests for addiction liability	710
H.1.3.6.1	General considerations	710
H.1.3.6.2	Drug discrimination studies	710
H.1.3.6.3	Place conditioning paradigm	713
<b>H.2</b>	<b>Peripheral analgesic activity</b>	716
H.2.0.1	General considerations	716
H.2.0.2	Writhing tests	716
H.2.0.3	Pain in inflamed tissue (RANDALL-SELITTO-test)	717
H.2.0.4	Mechanical visceral pain model in the rat	720
H.2.0.5	Antagonism against local effects of bradykinin	721
H.2.0.6	Effect of analgesics on spinal neurons	723
<b>H.3</b>	<b>Anti-inflammatory activity</b>	725
H.3.0.1	General considerations	725
H.3.1	<i>In vitro</i> methods for anti-inflammatory activity	726
H.3.1.1	General considerations	726
H.3.1.2	<sup>3</sup> H-Bradykinin receptor binding	726
H.3.1.3	Substance P and the tachykinin family	728
H.3.1.3.1	General considerations	728
H.3.1.3.2	<sup>3</sup> H-Substance P receptor binding	730
H.3.1.3.3	Neurokinin receptor binding	731
H.3.1.3.4	Characterization of neurokinin agonists and antagonists by biological assays	733
H.3.1.4	Assay of polymorphonuclear leukocyte chemotaxis <i>in vitro</i>	735
H.3.1.5	Polymorphonuclear leukocytes aggregation induced by FMLP	737
H.3.1.6	Constitutive and inducible cellular arachidonic acid metabolism <i>in vitro</i>	737
H.3.1.6.1	Formation of leukotriene B <sub>4</sub> in human white blood cells <i>in vitro</i>	738
H.3.1.6.2	Formation of lipoxygenase products from <sup>14</sup> C-arachidonic acid in human polymorphonuclear neutrophils (PMN) <i>in vitro</i>	738

---

H.3.1.6.3	Formation of eicosanoids from <sup>14</sup> C-arachidonic acid in human platelets <i>in vitro</i> .....	738	
H.3.1.6.4	Stimulation of inducible prostaglandin pathway in human PMNL ...	739	
H.3.1.6.5	COX-1 and COX-2 inhibition .....	740	
H.3.1.7	Induced release of cytokines (Interleukin-1alpha, IL-1beta, IL-6, IL-8 and TNF-alpha) from human white blood cells <i>in vitro</i> .....	744	
H.3.1.8	Flow cytometric analysis of intracellular cytokines .....	745	
H.3.1.9	TNF-alpha antagonism .....	746	
H.3.1.10	Binding to interferon receptors .....	747	
H.3.1.11	Screening for interleukin-1 antagonists .....	748	
H.3.1.12	Inhibition of interleukin-1 $\beta$ converting enzyme (ICE) .....	750	
H.3.2	<i>In vivo</i> methods for anti-inflammatory activity .....	751	
H.3.2.1	General considerations .....	751	
H.3.2.2	Methods for testing acute and subacute inflammation .....	752	
H.3.2.2.1	Ultraviolet erythema in guinea pigs .....	752	
H.3.2.2.2	Vascular permeability .....	753	
H.3.2.2.3	Inhibition of leukocyte adhesion to rat mesenteric venules <i>in vivo</i> ...	755	
H.3.2.2.4	Oxazolone-induced ear edema in mice .....	756	
H.3.2.2.5	Croton-oil ear edema in rats and mice .....	757	
H.3.2.2.6	Paw edema .....	759	
H.3.2.2.7	Pleurisy test .....	762	
H.3.2.2.8	Granuloma pouch technique .....	764	
H.3.2.2.9	Urate-induced synovitis .....	765	
H.3.2.3	Methods for testing the proliferative phase (granuloma formation) .....	767	
H.3.2.3.1	Cotton wool granuloma .....	767	
H.3.2.3.2	Sponge implantation technique .....	768	
H.3.2.3.3	Glass rod granuloma .....	769	
H.3.3	Side effects of anti-inflammatory compounds .....	769	
H.3.3.1	General considerations .....	769	
H.3.3.2	Ulcerogenic effect in rats .....	770	
H.3.3.3	Measurement of gastric mucosal damage by intragastric inulin ...	771	
H.3.3.4	Determination of blood loss .....	771	
<b>H.4</b>	<b>Antipyretic activity</b> .....	<b>772</b>	
H.4.0.1	General considerations .....	772	
H.4.0.2	Antipyretic testing in rats .....	772	
H.4.0.3	Antipyretic testing in rabbits .....	773	
 <b>Chapter I</b>			
<b>Antiarthrotic and immunomodulatory activity</b> .....			<b>775</b>
<b>I.1</b>	<b>Anti-arthrotic activity</b> .....	<b>775</b>	
I.1.0.1	General considerations .....	775	
I.1.1	<i>In vitro</i> methods for anti-osteoarthritic activity .....	776	
I.1.1.1	General considerations .....	776	
I.1.1.2	Modulation of cellular proteoglycan metabolism .....	777	
I.1.1.3	Cellular chondrocytic chondrolysis .....	779	
I.1.1.4	Cartilage explant chondrolysis .....	781	
I.1.2	<i>In vivo</i> methods for anti-osteoarthritic activity .....	782	
I.1.2.1	General considerations .....	782	
I.1.2.2	Canine anterior cruciate ligament (ACL) transection model .....	784	
I.1.2.3	Chymopapain-induced cartilage degeneration in the rabbit .....	786	
I.1.2.4	Spontaneous OA model in STR/IN mice .....	787	

<b>I.2</b>	<b>Methods for testing immunological factors</b> .....	788
I.2.1	<i>In vitro</i> methods .....	788
I.2.1.1	Inhibition of histamine release from mast cells .....	788
I.2.1.2	Mitogen induced lymphocyte proliferation .....	790
I.2.1.3	Inhibition of T cell proliferation .....	791
I.2.1.4	Chemiluminescence in macrophages .....	792
I.2.1.5	PFC (plaque forming colony) test <i>in vitro</i> .....	793
I.2.1.6	Inhibition of dihydro-oroate dehydrogenase .....	794
I.2.2	<i>In vivo</i> methods for testing immunological factors .....	795
I.2.2.1	Spontaneous autoimmune diseases in animals .....	795
I.2.2.2	Acute systemic anaphylaxis in rats .....	797
I.2.2.3	Anti-anaphylactic activity (Schultz-Dale reaction) .....	798
I.2.2.4	Passive cutaneous anaphylaxis .....	799
I.2.2.5	Arthus type immediate hypersensitivity .....	800
I.2.2.6	Delayed type hypersensitivity .....	800
I.2.2.7	Reversed passive Arthus reaction .....	801
I.2.2.8	Adjuvant arthritis in rats .....	802
I.2.2.9	Collagen type II induced arthritis in rats .....	806
I.2.2.10	Proteoglycan-induced progressive polyarthritis in mice .....	807
I.2.2.11	Experimental autoimmune thyroiditis .....	808
I.2.2.12	Coxsackievirus B3-induced myocarditis .....	809
I.2.2.13	Porcine cardiac myosin-induced autoimmune myocarditis in rats ...	810
I.2.2.14	Experimental allergic encephalomyelitis .....	811
I.2.2.15	Acute graft versus host disease (GVHD) in rats .....	813
I.2.2.16	Influence on SLE-like disorder in MRL/lpr mice .....	814
I.2.2.17	Prevention of experimentally induced myasthenia gravis in rats ...	816
I.2.2.18	Glomerulonephritis induced by antibasement membrane antibody in rats .....	818
I.2.2.19	Auto-immune uveitis in rats .....	820
I.2.2.20	Inhibition of allogenic transplant rejection .....	820
<b>Chapter J</b>		
<b>Activity on the gastrointestinal tract</b> .....		825
<b>J.1</b>	<b>Salivary glands</b> .....	827
J.1.0.1	Measurement of salivation .....	827
<b>J.2</b>	<b>Esophagus</b> .....	828
J.2.0.1	Tunica muscularis mucosae of esophagus <i>in vitro</i> .....	828
J.2.0.2	Esophageal sphincter <i>in vivo</i> .....	832
J.2.0.3	Permanent fistula of the esophagus in the dog .....	833
<b>J.3</b>	<b>Gastric function</b> .....	833
J.3.1	Acid secretion .....	833
J.3.1.1	Acid secretion in perfused rat stomach (Gosh and Schild rat) .....	833
J.3.1.2	Isolated rat stomach .....	835
J.3.1.3	Chronic gastric fistula in rats .....	835
J.3.1.4	Chronic gastric fistula in dogs .....	837
J.3.1.5	Heidenhain pouch in dogs .....	838
J.3.1.6	Gastrin activity .....	840
J.3.1.7	Receptor binding for gastrin .....	841
J.3.1.8	Gastrin releasing peptide/bombesin/neuromedin .....	842
J.3.1.9	Bombesin receptor binding .....	844
J.3.1.10	Evaluation of bombesin receptor antagonists as anti-cancer drugs ...	845

---

J.3.2	Mucus secretion .....	848
J.3.2.1	Isolated gastric mucosal preparation .....	848
J.3.2.2	Primary culture of rat gastric epithelial cells .....	849
J.3.3	Gastric motility .....	850
J.3.3.1	Measurement of intragastric pressure in rats .....	850
J.3.3.2	Isolated smooth muscle preparation of guinea pig stomach .....	851
J.3.4	Absorption .....	852
J.3.4.1	Measurement of gastric absorption of drugs in rats .....	852
J.3.5	Antacid activity .....	853
J.3.5.1	Evaluation of antacids .....	853
J.3.6	Inhibition of HCl secretion .....	854
J.3.6.1	Anticholinergic activity .....	854
J.3.6.1.1	General considerations .....	854
J.3.6.1.2	Acetylcholine receptor binding .....	854
J.3.6.2	H <sub>2</sub> -antagonism .....	857
J.3.6.2.1	General considerations .....	857
J.3.6.2.2	Histamine H <sub>2</sub> -receptor binding .....	858
J.3.6.2.3	H <sub>2</sub> -antagonism in isolated guinea pig right atria .....	859
J.3.6.2.4	H <sub>2</sub> -antagonism in isolated rat uterus .....	859
J.3.6.2.5	Activity at histamine H <sub>1</sub> - and H <sub>2</sub> -receptors <i>in vivo</i> .....	860
J.3.6.2.6	Inhibition of histamine stimulated adenylate cyclase from gastric mucosa .....	861
J.3.6.3	H <sup>+</sup> /K <sup>+</sup> -ATPase (proton pump) inhibition .....	861
J.3.6.3.1	General considerations .....	861
J.3.6.3.2	H <sup>+</sup> /K <sup>+</sup> -ATPase inhibition in membrane vesicles of stomach mucosa .....	862
J.3.6.3.3	Effect of H <sup>+</sup> /K <sup>+</sup> -ATPase inhibitors on serum gastrin levels .....	863
J.3.6.3.4	( <sup>14</sup> C)-aminopyrine uptake and oxygen consumption in isolated rabbit gastric glands .....	864
J.3.6.3.5	Gastric mucosal blood flow .....	866
J.3.7	Anti-ulcer activity .....	867
J.3.7.1	Pylorus ligation in rats (SHAY rat) .....	867
J.3.7.2	Stress ulcer through immobilization stress .....	868
J.3.7.3	Stress ulcers by cold water immersion .....	869
J.3.7.4	Indomethacin induced ulcers in rats .....	869
J.3.7.5	Ethanol induced mucosal damage in rats (cytoprotective activity) ..	870
J.3.7.6	Subacute gastric ulcer in rats .....	871
J.3.7.7	Gastric ischemia-reperfusion injury in rats .....	872
<b>J.4</b>	<b>Intestinal functions</b> .....	<b>873</b>
J.4.1	Intestinal secretion .....	873
J.4.1.1	Laxative activity in rats .....	873
J.4.1.2	Enteropooling test .....	874
J.4.1.3	Inhibition of chloride secretion in rabbit colon .....	874
J.4.2	Antidiarrhea effect .....	875
J.4.2.1	Castor oil induced diarrhea .....	875
J.4.2.2	Antidiarrheal effect in cecectomized rats .....	876
J.4.2.3	Evaluation of antidiarrheal effect in cold-restrained rats .....	877
J.4.3	Gut motility .....	878
J.4.3.1	Isolated ileum (MAGNUS technique) .....	878
J.4.3.2	Cascade superfusion technique .....	881
J.4.3.3	<i>In vivo</i> evaluation of spasmolytic activity in rats .....	882
J.4.3.4	Colon motility in anesthetized rats .....	882
J.4.3.5	Continuous recording of electrical and mechanical activity in the gut of the conscious rat .....	883
J.4.3.6	Propulsive gut motility in mice .....	884

---

J.4.3.7	Nerve-jejunum preparation of the rabbit .....	885
J.4.3.8	Motility of gastrointestinal tract in dogs .....	886
J.4.3.9	Thiry-Vella fistula .....	886
J.4.3.10	Continuous recording of mechanical and electrical activity in the intestine of conscious dogs .....	888
J.4.4	Absorption .....	890
J.4.4.1	Everted sac technique .....	890
J.4.4.2	Stomach emptying and intestinal absorption in rats .....	891
J.4.4.3	Intestinal drug absorption .....	893
J.4.5	Duodenal ulcer formation .....	894
J.4.5.1	Cysteamine-induced duodenal ulcers in rats .....	894
J.4.6	Models of inflammatory gut disease .....	895
J.4.6.1	Experimental ileitis .....	895
J.4.6.2	Experimental colitis .....	896
<b>J.5</b>	<b>Emetic and anti-emetic activity</b> .....	901
J.5.0.1	Assessment of emetic and anti-emetic activity in dogs .....	901
J.5.0.2	Anti-emetic activity in ferrets .....	902
J.5.0.3	Assessment of emetic and anti-emetic activity in pigeons .....	904
J.5.0.4	Activity against motion-induced emesis .....	904
J.5.0.5	Foot tapping in gerbils .....	905
<b>J.6</b>	<b>Gall bladder functions</b> .....	906
J.6.1	Bile secretion .....	906
J.6.1.1	Cholagogic activity in mice .....	906
J.6.1.2	Choleretic activity in rats .....	906
J.6.1.3	Chronic bile fistula in rats .....	907
J.6.1.4	Chronic bile fistula in dogs .....	909
J.6.2	Gall bladder motility .....	910
J.6.2.1	Activity on isolated gall-bladder strips from guinea pigs .....	910
J.6.2.2	Gallbladder motility in dogs .....	910
J.6.2.3	Cholecystokinin activity (isolated gallbladder or intestine) .....	911
J.6.3	Sphincter Oddi function .....	911
J.6.3.1	Relaxation of sphincter of Oddi <i>in vitro</i> .....	912
J.6.3.2	Function of sphincter of Oddi <i>in vivo</i> .....	913
<b>J.7</b>	<b>Pancreatic function</b> .....	914
J.7.0.1	Acute pancreatic fistula in rats .....	914
J.7.0.2	Exocrine secretion of isolated pancreas .....	915
J.7.0.3	Chronic pancreatic fistula in rats .....	916
J.7.0.4	Acute pancreatic fistula in dogs .....	917
J.7.0.5	Chronic pancreatic fistula in dogs .....	918
J.7.0.6	Somatostatin activity .....	919
J.7.0.7	Receptor binding for somatostatin .....	921
J.7.0.8	Secretin activity .....	924
J.7.0.9	Receptor binding for secretin .....	924
J.7.0.10	Cholecystokinin activity (isolated rat pancreatic acini) .....	926
J.7.0.11	Receptor binding of cholecystokinin .....	927
J.7.0.12	Acute experimental pancreatitis .....	931
J.7.0.13	Taurocholate-induced pancreatitis in the rat .....	933
J.7.0.14	Chronic pancreatitis .....	934
<b>J.8</b>	<b>Liver function</b> .....	936
J.8.1	Hepatocellular function .....	936
J.8.1.1	Hepatitis in Long Evans Cinnamon rats .....	936



J.8.1.2	Temporary hepatic ischemia .....	937
J.8.1.3	Model for direct transhepatic studies in dogs .....	938
J.8.2	Liver cirrhosis and necrosis .....	938
J.7.2.1	General considerations .....	938
J.8.2.2	Inhibition of proline hydroxylation .....	939
J.8.2.3	Influence on collagen synthesis in human skin fibroblasts .....	940
J.8.2.4	Influence on collagen synthesis in chicken calvaria .....	941
J.8.2.5	Allyl alcohol induced liver necrosis in rats .....	941
J.8.2.6	Carbontetrachloride induced liver fibrosis in rats .....	942
J.8.2.7	Bile duct ligation induced liver fibrosis in rats .....	943
J.8.2.8	Galactosamine induced liver necrosis .....	944
<b>J.9</b>	<b>Eviscerated animals</b> .....	<b>945</b>
J.9.1	Evisceration in rats .....	945
J.9.2	Evisceration in rabbits .....	945

## Chapter K

<b>Antidiabetic activity</b> .....	<b>947</b>	
<b>K.1</b>	<b>Methods to induce experimental diabetes mellitus</b> .....	<b>948</b>
K.1.0.1	Pancreatectomy in dogs .....	948
K.1.0.2	Alloxan induced diabetes .....	950
K.1.0.3	Streptozotocin induced diabetes .....	951
K.1.0.4	Other diabetogenic compounds .....	952
K.1.0.5	Hormone induced diabetes .....	952
K.1.0.6	Insulin deficiency due to insulin antibodies .....	953
K.1.0.7	Virus induced diabetes .....	953
<b>K.2</b>	<b>Genetically diabetic animals</b> .....	<b>954</b>
K.2.0.1	General considerations .....	954
K.2.0.2	Spontaneously diabetic rats .....	954
K.2.0.3	Spontaneously diabetic mice .....	958
K.2.0.4	Chinese hamster .....	961
K.2.0.5	Other species with inherited diabetic symptoms .....	962
K.2.0.6	Transgenic animals .....	964
<b>K.3</b>	<b>Assays of insulin and of insulin-like activity</b> .....	<b>965</b>
K.3.1	Hypoglycemic effects .....	965
K.3.1.1	Blood sugar lowering effect in rabbits .....	965
K.3.1.2	Hypoglycemic seizures in mice .....	967
K.3.1.4	Blood sugar determinations in mice .....	968
K.3.2	Insulin target cells/tissues of rats .....	968
K.3.2.1	Epididymal fat pad of rats .....	968
K.3.2.2	Fat cells isolated by digestion with collagenase .....	969
K.3.2.3	Primary culture of rat adipocytes .....	969
K.3.2.4	3T3 Adipocytes .....	969
K.3.2.5	Lipogenesis assay .....	970
K.3.2.6	Assays of glucose transport .....	971
K.3.2.7	Adipocyte plasma membranes .....	972
K.3.2.8	Effect on glucose transporter translocation .....	974
K.3.2.9	Influence on further metabolic functions .....	977
K.3.2.10	Insulin signaling cascade .....	980
K.3.2.11	Insulin signaling in the liver .....	983
K.3.2.12	Insulin receptor substrate .....	986



---

K.3.2.13	Effect of insulin on glycosyl-phosphatidylinositol-specific phospholipase C .....	991
K.3.2.14	Preparation of caveolae and detergent-insoluble glycolipid-enriched raft domains (DIGs) .....	994
K.3.3	Isolated diaphragm of rats or mice .....	999
K.3.3.1	Glycogen synthesis .....	999
K.3.3.2	Glucose transport .....	999
K.3.3.3	Glycogen synthase .....	1000
K.3.4	Binding assays .....	1001
K.3.4.1	Immunoassay .....	1001
K.3.4.2	Insulin receptor binding .....	1002
<b>K.4</b>	<b>Assays of other glucose regulating peptide hormones</b> .....	<b>1005</b>
K.4.0.1	Bioassay of glucagon .....	1005
K.4.0.2	Receptor binding and <i>in vitro</i> activity of glucagon .....	1006
K.4.0.3	Glucagon-like peptide I .....	1007
K.4.0.4	Insulin-like growth factors .....	1010
K.4.0.5	Amylin .....	1013
K.4.0.5.1	General considerations .....	1013
K.4.0.5.2	Receptor binding of amylin .....	1015
<b>K.5</b>	<b>Blood glucose lowering activity of antidiabetic drugs</b> .....	<b>1016</b>
K.5.0.1	Blood glucose lowering activity in rabbits .....	1016
K.5.0.2	Blood glucose lowering activity in rats .....	1016
K.5.0.3	Blood glucose lowering activity in dogs .....	1017
K.5.0.4	Euglycemic clamp technique .....	1018
K.5.0.5	Effects of insulin sensitizer drugs .....	1020
K.5.0.6	Effects of thiazolidinediones on peroxisome proliferator-activated receptor- $\gamma$ .....	1022
<b>K.6</b>	<b>Activity in isolated organs, cells, and membranes</b> .....	<b>1024</b>
K.6.1	Effects on pancreas .....	1024
K.6.1.1	Perfusion of isolated rat pancreas .....	1024
K.6.1.2	Perfusion of isolated rat pancreatic islets .....	1025
K.6.1.3	Insulin producing tumor cells .....	1026
K.6.1.4	Isolation of membranes .....	1028
K.6.1.5	Receptor binding of sulfonylureas .....	1028
K.6.1.6	Interaction of sulfonylureas with $\beta$ -cells .....	1030
K.6.1.7	Photoaffinity labeling of $\beta$ -cell membranes .....	1033
K.6.1.8	$^{86}\text{Rb}^+$ efflux measurements .....	1034
K.6.1.9	Membrane potential (measurement of the ATP sensitive potassium channel by voltage-clamp technique) .....	1035
K.6.2	Effects on liver .....	1036
K.6.2.1	Perfusion of isolated rat liver .....	1036
K.6.2.2	Isolated hepatocytes .....	1037
K.6.2.3	Fructose-2,6-bisphosphate production in rat hepatocytes .....	1038
K.6.3	Effects on muscle .....	1039
K.6.3.1	Perfused hind limb in rats .....	1039
K.6.3.2	Isolated diaphragm .....	1040
K.6.3.3	Activity on isolated muscle cells .....	1040
K.6.4	Effects on adipose tissue .....	1042
<b>K.7</b>	<b>Inhibition of polysaccharide degrading enzymes</b> .....	<b>1042</b>
K.7.0.1	General considerations .....	1042
K.7.0.2	Inhibition of $\alpha$ -amylase <i>in vitro</i> .....	1042

---

K.7.0.3	Inhibition of glucosidase <i>in vitro</i> .....	1043
K.7.0.4	Evaluation of $\alpha$ -glucosidase inhibitors using the everted sac technique .....	1043
K.7.0.5	Inhibition of glucose absorption <i>in vivo</i> .....	1043
<b>K.8</b>	<b>Effect on secondary diabetes symptoms</b> .....	1044
K.8.1	Inhibition of aldose reductase .....	1044
K.8.1.1	General considerations .....	1044
K.8.1.2	Aldose reductase inhibition <i>in vitro</i> .....	1045
K.8.1.3	Effect on nerve conduction velocity .....	1046
K.8.1.4	Effect on nerve blood flow (Doppler flux) .....	1047
K.8.1.5	Electroretinogram in diabetic hyperglycemia and galactosemia ....	1048
K.8.1.6	Effect on streptozotocin induced cataract .....	1049
K.8.1.7	Determination of aldose reductase in rat lens .....	1049
K.8.1.8	Effect on naphthalene induced cataract .....	1051
<b>Chapter L</b>		
<b>Anti-obesity activity</b> .....		1053
<b>L.1</b>	<b>Methods to induce experimental obesity</b> .....	1053
L.1.0.1	General considerations .....	1053
L.1.0.2	Food induced obesity .....	1054
L.1.0.3	Hypothalamic obesity .....	1055
L.1.0.4	Goldthioglucose-induced obesity .....	1056
L.1.0.5	Monosodium glutamate-induced obesity .....	1057
<b>L.2</b>	<b>Genetically obese animals</b> .....	1058
L.2.0.1	General considerations .....	1058
L.2.0.2	Spontaneously obese rats .....	1058
L.2.0.3	Spontaneously obese mice .....	1061
L.2.0.4	Transgenic animals .....	1065
<b>L.3</b>	<b>Assays of anti-obesity activity</b> .....	1065
L.3.1	Anorectic activity .....	1065
L.3.1.1	Food consumption in rats .....	1065
L.3.2	Metabolic activity .....	1068
L.3.2.1	GDP-binding in brown adipose tissue .....	1068
L.3.2.2	Uncoupling protein and GLUT4 in brown adipose tissue .....	1069
L.3.2.3	Resting metabolic rate .....	1072
L.3.2.4	$\beta_3$ -adrenoceptor .....	1074
<b>L.4</b>	<b>Assays of obesity regulating peptide hormones</b> .....	1075
L.4.0.1	Hormonal regulation of food intake .....	1075
L.4.1	Leptin .....	1078
L.4.1.1	General considerations on the obese gene product leptin .....	1078
L.4.1.2	Determination of leptin mRNA level in adipose tissue .....	1079
L.4.1.3	Determination of plasma leptin .....	1080
L.4.2	Neuropeptide Y .....	1081
L.4.2.1	General considerations on neuropeptide Y and related peptides .	1081
L.4.2.2	Receptor assay of neuropeptide Y .....	1083
L.4.3	Orexin .....	1085
L.4.3.1	General considerations on orexin .....	1085
L.4.3.2	Receptor assay of orexin .....	1086
L.4.3.3	Radioimmunoassay for orexin .....	1087

L.4.4	Galanin .....	1087
L.4.4.1	General considerations on galanin .....	1087
L.4.4.2	Receptor assay of galanin .....	1090
L.4.5	Adipsin .....	1091
L.4.5.1	General considerations on adipsin .....	1091
L.4.5.2	Adipsin expression in mice .....	1092

## Chapter M

### Anti-atherosclerotic activity ..... 1095

<b>M.1</b>	<b>Induction of experimental atherosclerosis</b> .....	1095
M.1.0.1	General considerations .....	1095
M.1.0.2	Cholesterol-diet induced atherosclerosis in rabbits and other species ..	1096
M.1.0.3	Hereditary hypercholesterolemia in rats .....	1099
M.1.0.4	Hereditary hyperlipemia in rabbits .....	1099
M.1.0.5	Transgenic animals .....	1099
M.1.0.6	Evaluation of endothelial function in rabbits with atherosclerosis ..	1100
M.1.0.7	Intimal reactions after endothelial injury .....	1101
<b>M.2</b>	<b>Influence on lipid metabolism</b> .....	1102
M.2.0.1	General considerations .....	1102
M.2.0.2	Hypolipidemic activity in rats .....	1103
M.2.0.3	Hypolipidemic activity in Syrian hamsters .....	1105
M.2.0.4	Triton-induced hyperlipidemia .....	1106
M.2.0.5	Fructose induced hypertriglyceridemia in rats .....	1107
M.2.0.6	Intravenous lipid tolerance test in rats .....	1107
M.2.0.7	Influence on lipoprotein-lipase activity .....	1108
M.2.0.8	Influence on several steps of cholesterol absorption and formation ..	1108
<b>M.3</b>	<b>Inhibition of cholesterol biosynthesis</b> .....	1111
M.3.1	General considerations on cholesterol biosynthesis .....	1111
M.3.2	Determination of HMG-CoA-reductase inhibitory activity .....	1113
M.3.2.1	General considerations on HMG-CoA reductase .....	1113
M.3.2.2	Inhibition of the isolated enzyme HMG-CoA-reductase <i>in vitro</i> ...	1114
M.3.2.3	Inhibition of the incorporation of <sup>14</sup> C sodium acetate into cholesterol in isolated liver cells .....	1115
M.3.2.4	<i>Ex vivo</i> inhibition of cholesterol biosynthesis in isolated rat liver slices ..	1116
M.3.2.5	Effect of HMG-CoA -reductase inhibitors <i>in vivo</i> .....	1117
<b>M.4</b>	<b>Inhibition of cholesterol absorption</b> .....	1118
M.4.1	Inhibition of ACAT (Acyl coenzyme A:cholesterol acyltransferase) ..	1118
M.4.1.1	General considerations .....	1118
M.4.1.2	<i>In vitro</i> ACAT inhibitory activity .....	1119
M.4.1.3	<i>In vivo</i> tests for ACAT inhibitory activity .....	1120
M.4.1.4	Lymph fistula model for cholesterol absorption .....	1121
<b>M.5</b>	<b>Interruption of bile acid recirculation</b> .....	1122
M.5.0.1	Cholestyramine binding .....	1122
<b>M.6</b>	<b>Inhibition of lipid oxidation</b> .....	1123
M.6.0.1	General considerations .....	1123
M.6.0.2	Inhibition of lipid peroxidation of isolated plasma low density lipoproteins .....	1123
M.6.0.3	Internalization of labeled LDL into HepG2 cells .....	1124

---

<b>Chapter N</b>		
<b>Endocrinology</b>	.....	1127
<b>N.1</b>	<b>Endocrine survey</b>	1130
<b>N.2</b>	<b>Adrenal steroid hormones</b>	1131
N.2.0.1	Adrenalectomy in rats	1131
N.2.1	Glucocorticoid activity	1131
N.2.1.1	<i>In vitro</i> methods for glucocorticoid hormones	1131
N.2.1.1.1	Corticoid receptor binding	1131
N.2.1.1.2	Transactivation assay for glucocorticoids	1135
N.2.1.1.3	Induction of tyrosine aminotransferase in hepatoma cells	1135
N.2.1.1.4	Effect on T-lymphocytes	1135
N.2.1.1.5	Inhibition of cartilage degradation	1137
N.2.1.2	<i>In vivo</i> methods for glucocorticoid hormones	1137
N.2.1.2.1	General considerations	1137
N.2.1.2.2	Adrenal and thymus involution	1138
N.2.1.2.3	Eosinopenia test in adrenalectomized mice	1138
N.2.1.2.4	Liver glycogen test in rats	1139
N.2.1.2.5	Anti-inflammatory tests	1139
N.2.1.3	Influence of steroids on mechanical properties of connective tissue	1140
N.2.1.3.1	Breaking strength of bones	1140
N.2.1.3.2	Tensile strength of femoral epiphyseal cartilage in rats	1141
N.2.1.3.3	Tensile strength of tail tendons in rats	1141
N.2.1.3.4	Tensile strength of skin strips in rats	1142
N.2.1.4	Topical activity of glucocorticosteroids	1143
N.2.1.4.1	Skin thickness and tensile strength	1143
N.2.1.4.2	Assay of topical glucocorticoid activity in transgenic mice	1145
N.2.1.4.3	Effect on epidermal DNA synthesis	1146
N.2.1.4.4	Induction of drug metabolizing enzymes	1146
N.2.1.4.5	Cornea inflammation in rabbits	1147
N.2.1.4.6	Endotoxin-induced uveitis in rats	1148
N.2.1.5	Anti-glucocorticoid activity	1148
N.2.1.5.1	Adrenal and thymus involution	1148
N.2.2	Mineralocorticoid activity	1149
N.2.2.1	<i>In vivo</i> methods	1149
N.2.2.1.1	General considerations	1149
N.2.2.1.2	Electrolyte excretion	1149
N.2.2.2	<i>In vitro</i> methods	1150
N.2.2.2.1	Mineralocorticoid receptor binding	1150
N.2.2.2.2	Transactivation assay for mineralocorticoids	1151
N.2.2.3	Antimineralocorticoid activity	1153
N.2.2.3.1	Electrolyte excretion	1153
<b>N.3</b>	<b>Ovarian hormones</b>	1154
N.3.0.1	Castration of female rats	1154
N.3.1	Estrogens	1154
N.3.1.1	<i>In vitro</i> methods	1154
N.3.1.1.1	Estrogen receptor binding	1154
N.3.1.1.2	Transactivation assay for estrogens	1156
N.3.1.1.3	Estrogen dependent cell proliferation	1158
N.3.1.2	<i>In vivo</i> methods	1159
N.3.1.2.1	Vaginal cornification	1159
N.3.1.2.2	Uterus weight	1159

---

N.3.1.2.3	Chick oviduct method .....	1160
N.3.1.3	Anti-estrogenic activity .....	1161
N.3.1.3.1	Antagonism of uterus weight increase due to estrogen treatment ...	1161
N.3.1.3.2	Aromatase inhibition .....	1161
N.3.1.3.3	Anti-estrogenic effect on MCF-7 breast cancer cells .....	1162
N.3.2	Progestational activity .....	1163
N.3.2.1	<i>In vitro</i> methods .....	1163
N.3.2.1.1	Gestagen receptor binding .....	1163
N.3.2.1.2	Transactivation assay for gestagens .....	1165
N.3.2.1.3	Alkaline phosphatase assay .....	1167
N.3.2.2	<i>In vivo</i> methods .....	1167
N.3.2.2.1	Clauberg (McPhail) test in rabbits .....	1167
N.3.2.2.2	Endometrial carbonic anhydrase .....	1168
N.3.2.2.3	Deciduoma formation .....	1169
N.3.2.2.4	Pregnancy maintenance .....	1169
N.3.2.3	Anti-progestational activity .....	1170
N.3.2.3.1	Progesterone antagonism .....	1170
N.3.2.3.2	Luteolytic effect of prostaglandins .....	1171
<b>N.4</b>	<b>Testicular steroid hormones</b> .....	<b>1172</b>
N.4.0.1	Castration of male rats .....	1172
N.4.0.2	Caponizing of cockerels .....	1172
N.4.1	Androgenic and anabolic activity .....	1173
N.4.1.1	<i>In vitro</i> methods .....	1173
N.4.1.1.1	Androgen receptor binding .....	1173
N.4.1.1.2	Transactivation assay for androgens .....	1175
N.4.1.2	<i>In vivo</i> methods .....	1176
N.4.1.2.1	Chicken comb method .....	1176
N.4.1.2.2	Weight of ventral prostate, seminal vesicles and musculus levator ani .....	1177
N.4.1.2.3	Nitrogen retention .....	1177
N.4.2	Anti-androgenic activity .....	1178
N.4.2.0.1	General considerations .....	1178
N.4.2.1	<i>In vitro</i> methods .....	1178
N.4.2.1.1	Inhibition of 5 $\alpha$ -reductase .....	1178
N.4.2.2	<i>In vivo</i> methods .....	1180
N.4.2.2.1	Chick comb method .....	1180
N.4.2.2.2	Antagonism of the effect of testosterone on weight of ventral prostate, seminal vesicles and musculus levator ani .....	1181
N.4.2.2.3	Anti-androgenic activity in female rats .....	1182
N.4.2.2.4	Intra-uterine feminizing/virilizing effect .....	1182
N.4.2.2.5	Anti-androgenic activity on sebaceous glands .....	1183
N.4.2.2.6	Anti-androgenic activity in the hamster flank organ .....	1183
N.4.2.2.7	Effect of 5 $\alpha$ -reductase inhibitors on plasma and tissue steroid levels .....	1183
<b>N.5</b>	<b>Thyroid hormones</b> .....	<b>1184</b>
N.5.0.1	General considerations .....	1184
N.5.0.2	Thyroidectomy .....	1185
N.5.1	<i>In vivo</i> tests for thyroid hormones .....	1186
N.5.1.1	Oxygen consumption .....	1186
N.5.1.2	Inhibition of iodine release .....	1187
N.5.1.3	Anti-goitrogenic activity .....	1187
N.5.1.4	Tensile strength of connective tissue in rats, modified for thyroid hormones .....	1188

---

N.5.2	Antithyroid drugs .....	1188
N.5.2.1	General considerations .....	1188
N.5.2.2	Inhibition of iodine uptake into the thyroid of rats .....	1189
N.5.2.3	Antithyroidal effect on oxygen consumption in iodine treated mice ..	1189
N.5.3	Calcitonin .....	1190
N.5.3.1	General considerations .....	1190
N.5.3.2	Decrease of serum calcium in rats .....	1190
N.5.3.3	Effect of calcitonin on osteoclasts <i>in vitro</i> .....	1191
N.5.3.4	Receptor binding and cAMP accumulation in isolated cells .....	1192
<b>N.6</b>	<b>Parathyroid hormone</b> .....	1194
N.6.0.1	General considerations .....	1194
N.6.0.2	Receptor binding assay for PTH .....	1195
N.6.0.3	PTH assay by serum calcium increase .....	1196
N.6.0.4	Serum phosphate decrease after PTH .....	1197
N.6.0.5	cAMP release in isolated perfused rat femur .....	1197
N.6.0.6	Renal and metatarsal cytochemical bioassay .....	1198
N.6.0.7	cAMP accumulation in cultured cells .....	1199
N.6.0.8	Anabolic activity in ovariectomized, osteopenic rats .....	1200
<b>N.7</b>	<b>Anterior pituitary hormones</b> .....	1201
N.7.0.1	Hypophysectomy in rats .....	1201
N.7.1	Gonadotropins .....	1202
N.7.1.0.1	General considerations .....	1202
N.7.1.1	Follicle-stimulating hormone (FSH) .....	1203
N.7.1.1.1	Ovarian weight in HCG-primed rats .....	1203
N.7.1.1.2	[ <sup>3</sup> H]thymidine uptake in cultured mouse ovaries .....	1204
N.7.1.1.3	Granulosa cell aromatase assay <i>in vitro</i> .....	1205
N.7.1.1.4	Sertoli cell aromatase assay <i>in vitro</i> .....	1206
N.7.1.1.5	Receptor binding assay for FSH .....	1207
N.7.1.2	Luteinizing hormone (LH) = Interstitial cell stimulating hormone (ICSH) .....	1208
N.7.1.2.1	Prostate weight in hypophysectomized rats .....	1209
N.7.1.2.2	Superovulation in immature rats .....	1209
N.7.1.2.3	Ascorbic acid depletion of ovaries in PMSG/HCG primed rats .....	1209
N.7.1.2.4	Testosterone production by Leydig cells <i>in vitro</i> induced by LH ...	1210
N.7.1.2.5	Receptor binding assay for LH .....	1211
N.7.1.3	Other gonadotropins .....	1212
N.7.1.4	Human chorionic gonadotropin (hCG) .....	1212
N.7.1.4.1	Corpus luteum formation in immature mice (Aschheim-Zondek test) .....	1212
N.7.1.4.2	Biological assay of hCG in immature male rats .....	1212
N.7.1.4.3	Receptor binding assay for hCG .....	1213
N.7.1.5	Human menopausal gonadotropin (hMG) .....	1213
N.7.1.5.1	Biological assay of hMG in immature rats .....	1213
N.7.1.6	Pregnant mares' serum gonadotropin (PMSG) .....	1214
N.7.1.6.1	Biological assay of PMSG in immature female rats .....	1214
N.7.1.7	Immunoassays of gonadotropins .....	1214
N.7.1.8	Gonadotropin inhibition .....	1214
N.7.1.8.1	General considerations .....	1214
N.7.1.8.2	Inhibition of gonadotropin secretion in intact animals .....	1215
N.7.1.8.3	Inhibition of ovulation and luteinization .....	1215
N.7.1.8.4	Ovary-spleen-transplantation .....	1216
N.7.1.8.5	Inhibition of fertility .....	1217
N.7.2	Prolactin .....	1218

---

N.7.2.1	General considerations .....	1218
N.7.2.2	Radioimmunoassay of rat prolactin .....	1218
N.7.2.3	Pigeon crop method .....	1218
N.7.2.4	Lactation in rabbits .....	1219
N.7.3	Growth hormone (GH) .....	1220
N.7.3.1	General considerations .....	1220
N.7.3.2	Weight gain in female rats ("growth plateaued rats") .....	1220
N.7.3.3	Tibia test in hypophysectomized rats .....	1221
N.7.3.4	<sup>35</sup> S uptake .....	1222
N.7.3.5	Inhibition of glucose uptake in adipocytes <i>in vitro</i> .....	1222
N.7.3.6	Eluted stain bioassay for human growth hormone .....	1223
N.7.3.7	Reverse hemolytic plaque assay for growth hormone .....	1224
N.7.3.8	Determination of growth hormone isoforms by 22-kD GH exclusion assay .....	1225
N.7.3.9	Steroid regulation of growth hormone receptor and GH-binding protein .....	1225
N.7.4	Adrenocorticotropin (ACTH) .....	1227
N.7.4.1	Adrenal ascorbic acid depletion .....	1227
N.7.4.2	Corticosterone blood levels in dexamethasone blocked rats .....	1228
N.7.4.3	<i>In vitro</i> corticosteroid release .....	1229
N.7.4.4	Thymus involution .....	1230
N.7.4.5	Receptor binding assay for ACTH .....	1231
N.7.5	Thyrotropin (TSH) .....	1232
N.7.5.1	General considerations .....	1232
N.7.5.2	Thyroid histology .....	1232
N.7.5.3	Iodine uptake .....	1233
N.7.5.4	TSH bioassay based on cAMP accumulation in CHO cells .....	1233
N.7.6	Hormones related to TSH .....	1234
N.7.6.1	General considerations .....	1234
N.7.6.2	Assay of exophthalmus-producing substance (EPS) in fishes .....	1234
N.7.6.3	Assay of long acting thyroid stimulating factor (LATS) in mice .....	1235
<b>N.8</b>	<b>Posterior pituitary hormones</b> .....	1236
N.8.0.1	General considerations .....	1236
N.8.1	Oxytocin .....	1237
N.8.1.1	Isolated uterus .....	1237
N.8.1.2	Chicken blood pressure .....	1238
N.8.1.3	Milk ejection in the lactating rabbit or rat .....	1239
N.8.1.4	Oxytocin receptor determination .....	1240
N.8.2	Vasopressin .....	1241
N.8.2.1	Hereditary vasopressin deficiency in rats (Brattleboro strain) .....	1241
N.8.2.2	Vasopressor activity .....	1242
N.8.2.3	Antidiuretic activity in the conscious rat .....	1243
N.8.2.4	Antidiuretic activity in the rat in ethanol anesthesia .....	1243
N.8.2.5	Spasmogenic activity of vasopressin in the isolated guinea pig ileum .....	1244
N.8.2.6	Vasopressin receptor determination .....	1244
<b>N.9</b>	<b>Hypothalamic hormones</b> .....	1247
N.9.1	Thyrotropin releasing hormone (TRH) .....	1247
N.9.1.1	General considerations .....	1247
N.9.1.2	TRH receptor binding assays .....	1247
N.9.1.3	Release of <sup>131</sup> I from thyroid glands of mice .....	1248
N.9.1.4	Release of TSH from rat anterior pituitary glands <i>in vitro</i> .....	1249
N.9.2	Luteinizing hormone releasing hormone (LH-RH) .....	1250
N.9.2.1	General considerations .....	1250



---

N.9.2.2	LH-RH receptor assays .....	1251
N.9.2.3	LH release in the ovariectomized estrogen-progesterone-blocked rat ..	1253
N.9.2.4	Gonadotropin release from anterior pituitary cells .....	1254
N.9.2.5	Radioimmunoassay of rat-LH .....	1255
N.9.2.6	Radioimmunoassay of rat-FSH .....	1256
N.9.2.7	Measurement of ascorbic acid depletion in ovaries of pseudo-pregnant rats .....	1256
N.9.2.8	Progesterone production in pseudopregnant rats .....	1257
N.9.2.9	Induction of ovulation in rabbits .....	1257
N.9.2.10	Induction of superovulation in immature rats .....	1258
N.9.2.11	Inhibition of experimentally induced endometriosis .....	1258
N.9.3	LH-RH antagonistic activity .....	1259
N.9.3.1	Testosterone suppression in rats .....	1259
N.9.3.2	Antioviulatory activity in rats .....	1260
N.9.3.3	Effect of repeated administration of LH-RH antagonists in rats ....	1261
N.9.3.4	Inhibition of gonadotropin release from anterior pituitary cultures ...	1262
N.9.3.5	Anti-tumor affect of LH-RH antagonists .....	1262
N.9.4	Corticotropin releasing hormone (CRH) .....	1263
N.9.4.1	General considerations .....	1263
N.9.4.2	<i>In vitro</i> assay for CRH activity .....	1265
N.9.4.3	<i>In vivo</i> bioassay of CRH activity .....	1266
N.9.4.4	Collection of hypophyseal portal blood in rats .....	1267
N.9.4.5	CRH receptor determination .....	1268
N.9.5	Growth hormone releasing hormone (GH-RH) .....	1270
N.9.5.1	Radioreceptor assay of growth hormone-releasing hormone .....	1270
N.9.5.2	Growth hormone release from rat pituitaries <i>in vitro</i> .....	1272
N.9.5.3	GH-RH bioassay by growth hormone release in rats .....	1274
<b>N.10</b>	<b>Other peptide hormones</b> .....	1274
N.10.1	Melanophore stimulating hormone .....	1274
N.10.1.1	Skin darkening in whole amphibia .....	1274
N.10.1.2	Assay in isolated amphibian skin .....	1275
N.10.1.3	Binding to the melanocortin receptor .....	1276
N.10.2	Relaxin .....	1278
N.10.2.1	General considerations .....	1278
N.10.2.2	Relaxin bioassay by pubic symphysis method in guinea pigs ....	1279
N.10.2.3	Relaxin bioassay in mice .....	1280
N.10.2.4	Inhibition of uterine motility .....	1280
N.10.2.5	Relaxin assay by interstitial collagenase activity in cultured uterine cervical cells .....	1281
N.10.2.6	Relaxin receptor binding .....	1282
N.10.3	Calcitonin gene-related peptide .....	1283
N.10.3.1	General considerations .....	1283
N.10.3.2	Receptor binding of CGRP .....	1286
N.10.4	Inhibin .....	1287
N.10.4.1	General considerations .....	1287
N.10.4.2	<i>In vitro</i> bioassay for inhibin .....	1288
N.10.5	Activin .....	1289
N.10.5.1	General considerations .....	1289
N.10.5.2	<i>In vitro</i> bioassay for activin .....	1290
N.10.6	Follistatin .....	1292
N.10.6.1	General considerations .....	1292
N.10.6.2	Immunoassay for follistatin .....	1292
N.10.7	Further peptide hormones discussed in chapters related to the respective indications .....	1294



---

<b>Chapter O</b>		
<b>Ophthalmologic activity</b>	.....	1295
<b>O.1</b>	<b>Introduction</b>	..... 1295
<b>O.2</b>	<b>Intraocular pressure</b>	..... 1295
O.2.1	Acute measurement of intraocular pressure	..... 1295
O.2.2	Measurement of intraocular pressure by telemetry	..... 1297
<b>O.3</b>	<b>Aqueous humor flow rate</b>	..... 1299
<b>O.4</b>	<b>Experimental glaucoma</b>	..... 1300
O.4.1	Alpha-chymotrypsin induced glaucoma	..... 1300
<b>O.5</b>	<b>Local anesthesia of the cornea</b>	..... 1302
<b>O.6</b>	<b>Experimental cataract formation</b>	..... 1302
<b>O.7</b>	<b>Models of eye inflammation</b>	..... 1303
O.7.1	Allergic conjunctivitis	..... 1303
O.7.2	Corneal inflammation	..... 1304
O.7.3	Auto-immune uveitis in rats	..... 1305
O.7.4	Ocular inflammation induced by paracentesis	..... 1307
O.7.5	Ocular inflammation by lens proteins	..... 1308
O.7.6	Proliferative vitreoretinopathy in rabbits	..... 1308
<b>Chapter P</b>		
<b>Pharmacological models in dermatology</b>	.....	1311
<b>P.1</b>	<b>Skin sensitization testing</b>	..... 1312
P.1.1	Guinea pig maximization assay	..... 1312
P.1.2	Popliteal lymph node hyperplasia assay	..... 1313
P.1.3	Local lymph node assay	..... 1314
<b>P.2</b>	<b>Experimental dermatitis</b>	..... 1314
P.2.1	Spontaneous dermatitis	..... 1315
P.2.1.1	NC/Nga mouse as model for atopic dermatitis	..... 1315
P.2.1.2	Moth-eaten mice	..... 1316
P.2.1.3	Spontaneous erythema in hairless rats	..... 1316
P.2.2	Contact dermatitis	..... 1316
P.2.2.1	Skin reaction in mice	..... 1316
P.2.2.2	Non-immunologic contact urticaria	..... 1318
<b>P.3</b>	<b>Pruritus models</b>	..... 1318
P.3.1	Studies in cpdm/cpdm mice	..... 1318
<b>P.4</b>	<b>Psoriasis models</b>	..... 1320
P.4.1	General considerations	..... 1320
P.4.2	<i>In vitro</i> studies with isolated cells	..... 1320
P.4.2.1	Cultured keratinocytes	..... 1320
P.4.2.2	Effect on T lymphocytes	..... 1321
P.4.3	Psoriasis models in normal animals	..... 1323
P.4.3.1	Mouse tail model for psoriasis	..... 1323
P.4.3.2	Rat ultraviolet ray B photodermatitis model for psoriasis	..... 1324

---

P.4.4	Psoriasisiform skin diseases in spontaneous mice mutations .....	1325
P.4.4.1	Flaky skin ( <i>fsn</i> ) mouse .....	1325
P.4.4.2	Asebia ( <i>ab/ab</i> ) mouse .....	1327
P.4.5	Psoriasisiform skin diseases in genetically modified animals .....	1327
P.4.6	Xenotransplantation of human psoriatic skin .....	1330
<b>P.5</b>	<b>Scleroderma models</b> .....	1331
P.5.1	Scleroderma models in chicken .....	1331
P.5.2	Scleroderma models in mice .....	1332
<b>P.6</b>	<b>Pemphigus models</b> .....	1333
P.6.1	Experimentally induced pemphigus in mice .....	1333
<b>P.7</b>	<b>Ichthyosis vulgaris models</b> .....	1334
P.7.1	Experimentally induced ichthyosis in mice .....	1334
<b>P.8</b>	<b>Xeroderma models</b> .....	1335
P.8.1	Experimentally induced xeroderma in mice .....	1335
<b>P.9</b>	<b>Acne models</b> .....	1336
P.9.1	Activity on sebaceous glands of rats .....	1336
P.9.2	Activity on sebaceous glands of the fuzzy rat .....	1337
P.9.3	Activity on ear sebaceous glands of Syrian hamsters .....	1338
P.9.4	Activity on ear sebaceous glands of rabbits .....	1339
P.9.5	Activity on the hamster flank organ .....	1340
P.9.6	Activity on the skin of the Rhino mouse .....	1341
P.9.7	Activity on the skin of the Mexican hairless dog .....	1343
P.9.8	<i>In vitro</i> sebocyte model .....	1343
<b>P.10</b>	<b>Skin mycosis</b> .....	1345
P.10.1	General considerations .....	1345
P.10.2	<i>In vitro</i> inhibitory activity .....	1345
P.10.3	<i>In vivo</i> activity in the guinea pig trichophytosis model .....	1345
P.10.4	Skin penetration .....	1346
<b>P.11</b>	<b>Biomechanics of skin</b> .....	1347
P.11.1	General considerations .....	1347
P.11.2	<i>In vitro</i> ( <i>ex vivo</i> ) experiments .....	1348
P.11.2.1	Stress-strain behavior .....	1348
P.11.2.1.1	Measurement of skin thickness, ultimate load, tensile strength, ultimate strain and modulus of elasticity .....	1348
P.11.2.1.2	Measurement of mechanical properties at low extension degrees ..	1350
P.11.2.1.3	Step phenomenon .....	1351
P.11.2.1.4	Anisotropy of skin .....	1352
P.11.2.1.5	Relaxation phenomenon .....	1353
P.11.2.1.6	Hysteresis experiment .....	1354
P.11.2.1.7	Isorheological point .....	1355
P.11.2.1.8	Creep experiments .....	1355
P.11.2.1.9	Repeated strain .....	1356
P.11.2.2	Thermocontraction .....	1356
P.11.3	<i>In vivo</i> experiments .....	1358
P.11.3.1	Stress-strain curves <i>in vivo</i> .....	1358
P.11.3.2	Repeated strain <i>in vivo</i> .....	1359
P.11.3.3	<i>In vivo</i> recovery after repeated strain .....	1359
P.11.4	Healing of skin wounds .....	1360

---

<b>P.12</b>	<b>Protection against UV light</b> .....	1362	
<b>P.13</b>	<b>Transepidermal water loss (TEWL)</b> .....	1364	
<b>P.14</b>	<b>Influence on hair growth</b> .....	1365	
<b>P.15</b>	<b>Cutaneous microcirculation</b> .....	1367	
P.15.1	General considerations .....	1367	
P.15.2	Laser Doppler velocimetry .....	1367	
P.15.3	Measurement of skin microcirculation by reflectance spectroscopy .	1368	
<b>Chapter Q</b>			
<b>Guidelines for the care and use of laboratory animals</b> .....			1369
<b>Q.1</b>	<b>Regulations for the care and use of laboratory animals in various countries</b> .....	1369	
<b>Q.2</b>	<b>Techniques of blood collection in laboratory animals</b> .....	1371	
Q.2.1	Introduction .....	1371	
Q.2.2	Aspects of animal welfare .....	1371	
Q.2.3	Total blood volume .....	1372	
Q.2.4	Terminal blood collection .....	1372	
Q.2.5	Non-terminal blood collection .....	1372	
Q.2.5.1	Single blood removal .....	1372	
Q.2.5.2	Multiple blood removal .....	1372	
Q.2.6	Technical aspects of blood removal .....	1373	
Q.2.6.1	Permanent venous cannulation .....	1373	
Q.2.6.2	Retro-orbital bleeding .....	1373	
Q.2.6.3	Cardiac puncture .....	1374	
<b>Q.3</b>	<b>Anesthesia of experimental animals</b> .....	1375	
Q.3.1	Introduction .....	1375	
Q.3.2	Local anesthesia .....	1375	
Q.3.3	General anesthesia .....	1375	
Q.3.3.1	Preparation .....	1375	
Q.3.3.2	Premedication .....	1375	
Q.3.3.2.1	Hydration and base excess .....	1375	
Q.3.3.2.2	Atropine .....	1376	
Q.3.3.2.3	Sedation and pain elimination .....	1376	
Q.3.3.3	Course of anesthesia .....	1376	
Q.3.3.4	Routes of general anesthesia .....	1377	
Q.3.3.4.1	Injection .....	1377	
Q.3.3.4.2	Inhalation .....	1377	
Q.3.3.4.3	Inhalation compounds .....	1378	
Q.3.3.5	Termination of anesthesia .....	1378	
Q.3.4	Postoperative analgesia .....	1380	
<b>Q.4</b>	<b>Euthanasia of experimental animals</b> .....	1380	
Q.4.1	Introduction .....	1380	
Q.4.2	Euthanasia .....	1380	
Q.4.2.1	Physical methods recommended for euthanasia of laboratory animals .....	1381	
Q.4.2.2	Chemical agents recommended for euthanasia of laboratory animals .....	1381	

Q.4.2.3	Methods and agents not to be used for euthanasia of laboratory animals .....	1382
Q.4.2.4	Recommended methods for euthanasia for specific animal species .....	1382
<b>Index</b>	.....	1385



<http://www.springer.com/978-3-540-42396-6>

Drug Discovery and Evaluation: Pharmacological Assays

Vogel, H.G. (Ed.)

2002, XLIV, 1408 p. With CD-ROM., Hardcover

ISBN: 978-3-540-42396-6